Combination of METAP2 inhibitor and CDK4 / 6 inhibitor in cancer treatment
Patent Information
- Application Number
- JP2023528148
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-03-25
- Filing Date
- 2021-11-10
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2041-11-10
AI Technical Summary
Existing CDK4/6 inhibitors, such as palbociclib, face therapeutic resistance in treating breast cancer due to factors like upregulation of CDK2, cyclin D and E, autophagy, and estrogen receptor changes, leading to limited effectiveness and disease progression.
Combining MetAP2 inhibitors with CDK4/6 inhibitors to treat cancer, administering both simultaneously or in close temporal proximity, to overcome resistance and enhance therapeutic efficacy.
The combination of MetAP2 and CDK4/6 inhibitors significantly reduces protein expression levels in tumors, including Rb, CDK2, and Akt, thereby inhibiting cancer cell proliferation and enhancing treatment effectiveness.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001] Cross-reference with related applications This application claims priority and benefit to U.S. Provisional Application No. 63 / 112,217, filed November 11, 2020, and U.S. Provisional Application No. 63 / 166,060, filed March 25, 2021. The aforementioned patent applications are incorporated herein by reference in their entirety. [Background technology]
[0002] Inhibitors of cyclin-dependent kinases CDK4 and CDK6, referred to herein as CDK4 / 6 inhibitors, are used to treat breast cancer, such as metastatic, hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative (HR+HER2-) breast cancer. Treatment resistance to this class of drugs, including palbociclib, the first CDK4 / 6 inhibitor approved by the Federal Drug Administration (FDA) as a cancer treatment, and other CDK4 / 6 inhibitors (such as abemaciclib and ribociclib), has been reported to be mediated through numerous factors, including upregulation of CDK2, cyclins D and E, increased autophagy, alterations in Akt protein and estrogen receptors, and other mechanisms of action. Furthermore, improvements in overall survival (OS) with palbociclib or other CDK4 / 6 inhibitors have only been demonstrated to a limited extent at present, because resistance to these drugs develops in the majority of patients, ultimately leading to disease progression. Another proposed mediator of CDK4 / 6 resistance is through increased intracellular protein recycling (autophagy), which allows cells to replicate at an accelerated rate. Therefore, there is a need in the art for compositions and methods that reduce treatment resistance and enhance the efficacy of CDK4 / 6 inhibitors. This disclosure provides a combination of a MetAP2 inhibitor and a CDK4 / 6 inhibitor for the treatment of cancer. [Overview of the project]
[0003] This disclosure provides a combination for use in the treatment of cancer, comprising at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof.
[0004] This disclosure provides a method for treating cancer in a subject requiring cancer treatment, comprising administering at least one therapeutically effective dose of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one therapeutically effective dose of at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof to the subject.
[0005] This disclosure provides a MetAP2 inhibitor or a pharmaceutically acceptable salt thereof for use in a method of treating cancer, wherein the method further comprises administering at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof.
[0006] This disclosure provides a CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof for use in a method of treating cancer, wherein the method further comprises administering at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof.
[0007] In some embodiments, at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof are administered simultaneously or in close proximity in time.
[0008] This disclosure provides a method for treating cancer in a subject requiring cancer treatment, comprising administering at least one therapeutically effective dose of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one therapeutically effective dose of at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof to the subject.
[0009] This disclosure provides combinations of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof, combined with at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof, for use in the manufacture of pharmaceuticals for the treatment of cancer.
[0010] This disclosure provides a combination of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof for use in the treatment of cancer.
[0011] This disclosure provides a combination therapeutic agent comprising at least one therapeutically effective dose of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one therapeutically effective dose of at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof.
[0012] This disclosure provides a pharmaceutical composition comprising at least one therapeutically effective amount of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one therapeutically effective amount of at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof.
[0013] This disclosure provides a kit comprising at least one therapeutically effective dose of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one therapeutically effective dose of at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof.
[0014] This disclosure provides a method for treating cancer in a subject in need of cancer treatment, comprising administering to the subject in need at least one therapeutically effective amount of the combination therapeutic agent described in claim 4, the pharmaceutical composition described in claim 5, or the kit described in claim 6.
[0015] MetAP2 inhibitors are expressed by formula (I): [ka] Compounds represented by [In the formula, in each case independently, R4 is H or C1-C6 alkyl. R5 is H or C1-C6 alkyl. R6 is a C2-C6 hydroxyalkyl group. Z is -NH-AA1-AA2-AA3-AA4-AA5-AA6-C(O)-L or NH-AA1-AA2-AA3-AA4-AA5-AA6-C(O)-QXYC(O)-W, AA1 is glycine, alanine, or H2N(CH2) m It is CO2H, and m is 2, 3, 4, or 5. AA2 is a bond, or alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, or tyrosine. AA3 is a bound, or alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, or tyrosine. AA4 is a bound, or alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, or tyrosine. AA5 is a bond, or glycine, valine, tyrosine, tryptophan, phenylalanine, methionine, leucine, isoleucine, or asparagine. AA6 is bound to, or to alanine, asparagine, citrulline, glutamine, glycine, leucine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine, or H2N(CH2) m It is CO2H, and m is 2, 3, 4, or 5. L is -OH, -O-succinimide, -O-sulfosuccinimide, alkoxy, aryloxy, acyloxy, aroyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, -NH2, -NH(C2~C6 hydroxyalkyl), halide, or perfluoroalkyloxy. Q is NR, O, or S, X is M-(C(R)2) p -MJM-(C(R)2) p -It's a music video, M is a bond or C(O), J is a bond, or ((CH2) q Q) r , C5-C8 cycloalkyl, aryl, heteroaryl, NR, O, or S, Y is NR, O, or S, R is either H or alkyl. V is combined or [ka] And, R9 is alkyl, aryl, aralkyl, or bonded, or R9 together with Y forms a heterocycle. R 10 However, it is an amide or bond, R 11 However, it is H or alkyl, W is either a MetAP2 inhibitor moiety or an alkyl group. x is in the range of 1 to approximately 450. y is in the range of 1 to approximately 30. n is in the range of 1 to approximately 100. p is between 0 and 20. q is 2 or 3, [r is 1, 2, 3, 4, 5, or 6] Or it may be a pharmaceutically acceptable salt, prodrug, metabolite, analog, or derivative thereof.
[0016] MetAP2 inhibitors are [ka] Or it may be a pharmaceutically acceptable salt, prodrug, metabolite, analog, or derivative thereof.
[0017] MetAP2 inhibitors are [ka] Or it may be a pharmaceutically acceptable salt, prodrug, metabolite, analog, or derivative thereof.
[0018] MetAP2 inhibitors are [ka] Or it may be a pharmaceutically acceptable salt, prodrug, metabolite, analog, or derivative thereof.
[0019] MetAP2 inhibitors are [ka] Or it may be a pharmaceutically acceptable salt, analog, derivative, salt, or ester thereof.
[0020] In some embodiments, X may be in the range of 1 to about 450. In some embodiments, Y may be in the range of 1 to about 30. In some embodiments, n may be in the range of 1 to about 100.
[0021] In some embodiments, the MetAP2 inhibitor is [ka] It is possible.
[0022] In some embodiments, the MetAP2 inhibitor is [ka] It is possible.
[0023] In some embodiments, R4 may be methyl. In some embodiments, R5 may be methyl. In some embodiments, R6 may be 2-hydroxypropyl.
[0024] In some embodiments, Z may be -NH-AA6-C(O)-QXYC(O)-W. In some embodiments, AA6 may be glycine.
[0025] In some embodiments, Z may be -NH-AA5-AA6-C(O)-QXYC(O)-W. In some embodiments, AA5 may be leucine and AA6 may be glycine. In some embodiments, AA5 may be valine and AA6 may be glycine. In some embodiments, AA5 may be phenylalanine and AA6 may be glycine. In some embodiments, AA5 may be glycine and AA6 may be glycine.
[0026] In some embodiments, Z may be -NH-AA3-AA4-AA5-AA6-C(O)-QXYC(O)-W. In some embodiments, AA5 may be leucine, and each of AA3, AA4, or AA6 may be glycine. In some embodiments, AA5 may be valine, and each of AA3, AA4, or AA6 may be glycine. In some embodiments, AA5 may be phenylalanine, and each of AA3, AA4, or AA6 may be glycine. In some embodiments, AA3 may be glycine, AA4 may be phenylalanine, AA5 may be leucine, and AA6 may be glycine. In some embodiments, each of AA3, AA4, AA5, and AA6 may be glycine.
[0027] In some embodiments, -QXY is [ka] It is possible.
[0028] In some embodiments, W is [ka] It is possible.
[0029] In some embodiments, the ratio of x to y may be in the range of about 30:1 to about 3:1. In some embodiments, the ratio of x to y may be about 11:1.
[0030] CDK4 / 6 inhibitors include palbociclib, abemaciclib, ribociclib, trilaciclib, SHR-6390, FCN-437c, relociclib, milcilib, PF-06873600, XZP-3287, zotiraciclib, BEBT-209, BPI-16350, CS-3002, fadracilib, HS-10342, ON-123300, PF-06842874, and TQ. The following are selected from -05510, BPI-1178, JS-101, NUV-422, AU-294, CCT-68127, ETH-155008, HEC-80797, JRP-890, JS-104, NEOS-518, PF-07104091, PF-07220060, RMC-4550, SRX-3177, VS-2370, VS-2370, or pharmaceutically acceptable salts thereof. The CDK4 / 6 inhibitor may be palbociclib or a pharmaceutically acceptable salt thereof. The CDK4 / 6 inhibitor may be abemaciclib or a pharmaceutically acceptable salt thereof. The CDK4 / 6 inhibitor may be ribociclib or a pharmaceutically acceptable salt thereof.
[0031] MetAP2 inhibitors can be administered by subcutaneous injection. CDK4 / 6 inhibitors may be administered orally.
[0032] Cancer may be carcinoma, lymphoma, blastoma, sarcoma, leukemia, brain cancer, breast cancer, blood cancer, bone cancer, lung cancer, skin cancer, liver cancer, ovarian cancer, bladder cancer, kidney cancer, renal cancer, gastric cancer, thyroid cancer, pancreatic cancer, esophageal cancer, prostate cancer, cervical cancer, uterine cancer, stomach cancer, soft tissue cancer, laryngeal cancer, small intestine cancer, testicular cancer, anal cancer, vulvar cancer, joint cancer, oral cancer, pharyngeal cancer, or colorectal cancer. Cancer may be breast cancer. Breast cancer may be HR+HER2- breast cancer.
[0033] This disclosure relates to a method for treating breast cancer in a person requiring treatment for breast cancer, comprising: a) at least one therapeutically effective amount of compound 1: [ka] The present invention provides a method comprising: a) administering to a subject at least one therapeutically effective dose of palbociclib or a pharmaceutically acceptable salt thereof, prodrug, metabolite, analog, or derivative thereof (wherein x is in the range of 1 to about 450, y is in the range of 1 to about 30, and n is in the range of 1 to about 100); and b) administering to a subject at least one therapeutically effective dose of palbociclib or a pharmaceutically acceptable salt thereof.
[0034] This disclosure relates to a method for treating breast cancer in a person requiring treatment for breast cancer, comprising: a) at least one therapeutically effective amount of compound 1: [ka] The present invention provides a method comprising: a) administering to a subject at least one therapeutically effective dose of ribociclib or a pharmaceutically acceptable salt thereof, prodrug, metabolite, analog, or derivative thereof (wherein x is in the range of 1 to about 450, y is in the range of 1 to about 30, and n is in the range of 1 to about 100); and b) administering at least one therapeutically effective dose of ribociclib or a pharmaceutically acceptable salt thereof.
[0035] Any of the above embodiments or any other embodiments described herein may be combined with any other embodiments.
[0036] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art in which this disclosure belongs. In this specification, unless the context clearly indicates otherwise, singular forms include plural forms; for example, the terms “a,” “an,” and “the” are understood to be singular or plural, and the term “or” is understood to be inclusive. For example, “an element” means one or more elements. Throughout this specification, the word “comprising” or variations such as “comprise” or “comprising” are understood to mean encompassing the elements, integers, or steps, or groups of elements, integers, or steps described herein, but not to exclude any other elements, integers, or steps, or groups of elements, integers, or steps. "Approximately" can be understood as being within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clearly indicated in the context, all figures provided herein are modified by the term "approximately."
[0037] Methods and materials similar to or equivalent to those described herein may be used in the practice or testing of this disclosure, but preferred methods and materials are described below. All publications, patent applications, patents, and other references referenced herein are incorporated by reference in their entirety. References cited herein are not considered prior art to the inventions described in the claims. In case of any conflict, the present specification, including definitions, shall prevail. Furthermore, the materials, methods, and examples are illustrative and not intended to limit the scope. Other features and advantages of this disclosure will become apparent from the following detailed description and claims. [Brief explanation of the drawing]
[0038] The above and further features will be more clearly understood from the following detailed description in conjunction with the attached drawings.
[0039] [Figure 1] Figure 1 is a graph showing the MCF tumor volume in mice throughout the treatment process, where mice were treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 2] Figure 2 is a graph showing the MCF tumor volume in mice at the end of treatment. Mice were treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 3] Figure 3 is a graph showing the body weight of mice throughout the treatment process, with mice treated as a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 4] Figure 4 shows a series of graphs illustrating the survival rates of mice throughout the treatment process, with mice treated as a vehicle control, with a combination of compound 1 and palbociclib, with compound 1 alone, or with palbociclib alone. [Figure 5] Figure 5 is a graph showing the expression levels of cyclin D1 protein in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 6] Figure 6 is a graph showing the expression levels of cyclin E1 protein in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 7] Figure 7 is a graph showing the expression levels of cyclin E2 protein in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 8]Figure 8 is a graph showing the expression levels of the p21 protein in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 9] Figure 9 is a graph showing the expression levels of the CDK4 protein in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 10] Figure 10 is a graph showing the expression levels of the CDK2 protein in tumor samples collected at the end of treatment, in which mice were treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 11] Figure 11 is a graph showing the expression levels of Rb protein in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 12] Figure 12 is a graph showing the expression levels of LC3B protein in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 13] Figure 13 is a graph showing the expression levels of Akt protein in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 14] Figure 14 is a graph showing the expression levels of phospho-Akt protein in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 15]Figure 15 is a graph showing the expression levels of estrogen receptor alpha (ERα)-62kDa protein in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 16] Figure 16 is a graph showing the expression levels of ERα-55kDa protein in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 17] Figure 17 is a graph showing the total expression levels of ERα-55kDa and ERα-62kDa proteins in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 18] Figure 18 is a graph showing the expression levels of PHGDH protein in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 19] Figure 19 is a graph showing the amount of neutrophils in whole blood samples collected at the end of the study, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 20] Figure 20 is a graph showing the expression levels of PHGDH in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 21] Figure 21 is a graph showing the expression levels of PSPH in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 22]Figure 22 is a graph showing the expression levels of TYMS in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 23] Figure 23 is a graph showing the expression levels of MTHFD1L in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 24] Figure 24 is a graph showing the expression levels of MTHFD1 in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 25] Figure 25 is a graph showing the expression levels of MTHFD2 in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 26] Figure 26 is a graph showing the expression levels of SHMT1 in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 27] Figure 27 is a graph showing the expression levels of SHMT2 in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 28] Figure 28 is a graph showing the expression levels of PIK3IP1 in tumor samples collected at the end of treatment, in which mice were treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 29]Figure 29 is a graph showing the expression levels of Greb1 in tumor samples collected at the end of treatment, in which mice were treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 30] Figure 30 shows Kaplan-Meier plots of ER+ breast cancer patients with high or low PHGDH expression (N=5526). [Figure 31] Figure 31 shows Kaplan-Meier plots of ER+ breast cancer patients with high or low TYMS expression (N=5526). [Figure 32] Figure 32 shows Kaplan-Meier plots of ER+ breast cancer patients with high or low expression of PIK3IP1 (N=5526). [Figure 33] Figure 33 is a graph showing the expression levels of DHFR in tumor samples collected at the end of treatment, in which mice were treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 34] Figure 34 is a graph showing the expression levels of MybL2 in tumor samples collected at the end of treatment, in which mice were treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 35] Figure 35 is a graph showing the expression levels of BIRC5 / survivin in tumor samples collected at the end of treatment, in which mice were treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 36] Figure 36 is a graph showing the expression levels of Ki-67 in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 37]Figure 37 is a graph showing the expression levels of CCNB1 / cyclin B1 in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 38] Figure 38 is a graph showing the expression levels of SCUBE2 in tumor samples collected at the end of treatment, in which mice were treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 39] Figure 39 is a graph showing the expression levels of RRM2 in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 40] Figure 40 is a graph showing the expression levels of PCLAF in tumor samples collected at the end of treatment, in which mice were treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 41] Figure 41 is a graph showing the expression levels of SLC7A5 / LAT1 in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 42] Figure 42 is a graph showing the expression levels of SLC3A2 in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 43] Figure 43 is a graph showing the expression levels of EVL in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 44]Figure 44 is a graph showing the expression levels of ANP32E in tumor samples collected at the end of treatment, in which mice were treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 45] Figure 45 is a graph showing the expression levels of H2AZ1 in tumor samples collected at the end of treatment, in which mice were treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 46] Figure 46 is a graph showing the expression levels of H2AX in tumor samples collected at the end of treatment, with mice treated with either a vehicle control, a combination of compound 1 and palbociclib, compound 1 alone, or palbociclib alone. [Figure 47] Figure 47 is a graph showing the MCF tumor volume in mice over a 14-day treatment period, where mice were treated with either a vehicle control, a combination of compound 1 and ribociclib, compound 1 alone, or ribociclib alone. [Figure 48] Figure 48 is a graph showing the MCF tumor volume in mice on day 14 of treatment. Mice were treated with either a vehicle control, a combination of compound 1 and ribociclib, compound 1 alone, or ribociclib alone. [Figure 49] Figure 49 is a graph showing the MCF tumor volume in mice over an 18-day treatment period, where mice were treated with either a vehicle control, a combination of compound 1 and ribociclib, compound 1 alone, or ribociclib alone. [Figure 50] Figure 50 is a graph showing the MCF tumor volume in mice on day 18 of treatment. Mice were treated with either a vehicle control, a combination of compound 1 and ribociclib, compound 1 alone, or ribociclib alone. [Modes for carrying out the invention]
[0040] This disclosure provides, in particular, a method for treating cancer or preventing treatment resistance to cancer, comprising administering to a subject in need at least one therapeutically effective dose of at least one MetAP2 inhibitor or pharmaceutically acceptable salt thereof and at least one therapeutically effective dose of at least one CDK4 / 6 inhibitor or pharmaceutically acceptable salt thereof.
[0041] This disclosure provides a combination therapeutic agent comprising at least one therapeutically effective dose of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one therapeutically effective dose of at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof.
[0042] This disclosure provides a method for treating cancer in a subject in need of cancer treatment, comprising administering to the subject in need at least one therapeutically effective amount of the aforementioned combination therapeutic agent.
[0043] This disclosure provides a method for preventing and / or reducing treatment resistance in subjects requiring prevention and / or reduction of treatment resistance, comprising administering at least one therapeutically effective amount of the aforementioned combination therapeutic agent to subjects requiring prevention and / or reduction of treatment resistance.
[0044] This disclosure provides a pharmaceutical composition comprising at least one therapeutically effective amount of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one therapeutically effective amount of at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof.
[0045] This disclosure provides a method for treating cancer in a subject in need of cancer treatment, comprising administering at least one therapeutically effective amount of the aforementioned pharmaceutical composition to the subject in need of treatment.
[0046] This disclosure provides a method for preventing and / or reducing treatment resistance in a subject requiring prevention and / or reduction of treatment resistance, comprising administering at least one therapeutically effective amount of the aforementioned pharmaceutical composition to the subject requiring prevention and / or reduction.
[0047] This disclosure provides a kit comprising at least one therapeutically effective dose of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one therapeutically effective dose of at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof.
[0048] This disclosure provides a method for treating cancer in a subject in need of cancer treatment, comprising administering at least one therapeutically effective dose of the aforementioned kit to the subject in need of treatment.
[0049] This disclosure provides a method for preventing and / or reducing treatment resistance in subjects requiring prevention and / or reduction of treatment resistance, comprising administering at least one therapeutically effective dose of the aforementioned kit to the subject.
[0050] This disclosure provides a method for treating cancer in a subject requiring cancer treatment, comprising administering at least one therapeutically effective dose of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one therapeutically effective dose of at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof to the subject.
[0051] This disclosure provides a method for preventing and / or reducing treatment resistance in subjects requiring prevention and / or reduction of treatment resistance, comprising administering at least one therapeutically effective dose of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one therapeutically effective dose of at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof to the subject.
[0052] This disclosure provides the use of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof in combination with at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a pharmaceutical for the treatment of cancer.
[0053] This disclosure provides the use of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof in combination with at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for preventing and / or reducing treatment resistance in subjects requiring prevention and / or reduction of treatment resistance.
[0054] This disclosure provides the use of at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof in combination with at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof of this disclosure in the manufacture of a pharmaceutical for the treatment of cancer.
[0055] This disclosure provides the use of at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof in combination with at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof of this disclosure in the manufacture of a medicament for preventing and / or reducing treatment resistance in subjects requiring prevention and / or reduction of treatment resistance.
[0056] This disclosure provides combinations of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof, in combination with at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof, for use in the manufacture of a pharmaceutical product for the treatment of cancer.
[0057] This disclosure provides combinations of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof of the present disclosure in combination with at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for preventing and / or reducing treatment resistance in subjects requiring prevention and / or reduction of treatment resistance.
[0058] In some aspects of the methods and uses described above, treatment resistance may be resistance to treatment with CDK4 / 6 inhibitors.
[0059] This disclosure provides at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof for use in combination with at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof in the treatment of cancer.
[0060] This disclosure provides at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof for use in combination with at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof in subjects requiring prevention and / or reduction of treatment resistance.
[0061] This disclosure provides at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof for use in combination with at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof of this disclosure in the treatment of cancer.
[0062] This disclosure provides at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof for use in combination with at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof of this disclosure in subjects requiring prevention and / or reduction of treatment resistance.
[0063] This disclosure provides a combination of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof for use in the treatment of cancer.
[0064] This disclosure provides a combination of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof for use in preventing and / or reducing treatment resistance in subjects requiring prevention and / or reduction of treatment resistance.
[0065] This disclosure provides combinations for use in the treatment of cancer, comprising at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof. This disclosure provides combinations for use in the treatment of cancer, comprising at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof, comprising at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof. This disclosure provides combinations for use in the treatment of cancer, comprising at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof, comprising at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof. In some embodiments, at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof may be administered simultaneously, separately, or sequentially. In some embodiments, at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof may be administered simultaneously or in close proximity in time.
[0066] In some aspects of the methods and uses described above, treatment resistance may be resistance to at least one CDK4 / 6 inhibitor.
[0067] In some embodiments, a MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and a CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof may be administered via the same route of administration. In some embodiments, a MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and a CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof may be administered via different routes of administration.
[0068] In some embodiments, a MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and a CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof can be administered simultaneously.
[0069] In some embodiments, a MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and a CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof may be administered in close proximity in time.
[0070] As used herein, the term “temporal proximity” means that the administration of one therapeutic agent (e.g., a MetAP2 inhibitor compound disclosed herein) occurs within a period immediately preceding or succeeding the administration of another therapeutic agent (e.g., palbociclib). In other words, the therapeutic effect of one therapeutic agent overlaps with the therapeutic effect of the other. In some embodiments, the therapeutic effect of one therapeutic agent completely overlaps with the therapeutic effect of the other. In some embodiments, “temporal proximity” means that the administration of one therapeutic agent occurs within a period immediately preceding or succeeding the administration of another therapeutic agent in such a way that there is a synergistic effect between the two. “Temporal proximity” can vary according to a variety of factors, including but not limited to the age, sex, weight, genetic background, medical condition, medical history, and treatment history of the subject to whom the therapeutic agent is administered; the disease or condition being treated or improved; the therapeutic outcome achieved; the dosage, frequency, and duration of administration of the therapeutic agent; the pharmacokinetics and pharmacodynamics of the therapeutic agent; and the route through which the therapeutic agent is administered. In some embodiments, “temporal proximity” means within 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 18 hours, 24 hours, 2 hours, 36 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, or 8 weeks. In some embodiments, multiple doses of one therapeutic agent can be administered in temporal proximity to a single dose of another therapeutic agent. In some embodiments, temporal proximity can be varied during a treatment cycle or within a dosing regimen.
[0071] In some embodiments, administration of a combination of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof can result in a reduction in the expression level of at least one protein in at least one tumor of interest. In some embodiments, the at least one protein may include Rb protein, CDK2 protein, CDK4 protein, cyclin E1 protein, cyclin E2 protein, Akt protein, phospho-Akt, ERα-62, ERα-55, or any combination thereof. In some embodiments, a decrease in the expression level of at least one protein may be a decrease of at least about 5%, or at least about 10%, or at least about 15%, or at least about 20%, or at least about 25%, or at least about 30%, or at least about 35%, or at least about 40%, or at least about 45%, or at least about 50%, or at least about 55%, or at least about 60%, or at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 99%.
[0072] In some embodiments, administration of a combination of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof can result in a reduction in the expression level of at least one gene encoding at least one protein in at least one tumor of interest. In some embodiments, the at least one protein may include Rb protein, CDK2 protein, CDK4 protein, cyclin E1 protein, cyclin E2 protein, Akt protein, phospho-Akt, ERα-62, ERα-55, PHGDH, or any combination thereof. In some embodiments, a decrease in the expression level of at least one gene encoding at least one protein may be a decrease of at least about 5%, or at least about 10%, or at least about 15%, or at least about 20%, or at least about 25%, or at least about 30%, or at least about 35%, or at least about 40%, or at least about 45%, or at least about 50%, or at least about 55%, or at least about 60%, or at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 99%.
[0073] In some embodiments, administration of a combination of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof can result in a reduction in the expression level of at least one gene in at least one tumor of interest. In some embodiments, the at least one gene may include MTHFD1L, TYMS, ALDH1L1, MTHFD1, MTHFD2, GART, SHMT1, DHFR, MTR, SHMT2, and MTFMT, or any combination thereof. In some embodiments, at least one gene may include PHGDH, PSPH, TYMS, MTHFD1L, MTHFD1, MTHFD2, SHMT1, SHMT2, Greb1, DHFR, MybL2, BIRC5 / survivin, Ki-67, CCNB1 / cyclin B1, RRM2, PCLAF, SLC7A5 / LAT1, SLC3A2, ANP32E, H2AZ1, H2AX, or any combination thereof. In some embodiments, a decrease in the expression level of at least one gene may result in a decrease of at least about 5%, or at least about 10%, or at least about 15%, or at least about 20%, or at least about 25%, or at least about 30%, or at least about 35%, or at least about 40%, or at least about 45%, or at least about 50%, or at least about 55%, or at least about 60%, or at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 99%.
[0074] In some embodiments, the reduction in the expression level of at least one protein, at least one gene encoding at least one protein, or at least one gene upon administration of a combination of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof may be a greater reduction in expression level compared to the reduction in expression level caused by administration of at least one MetAP2 inhibitor alone and / or at least one CDK4 / 6 inhibitor alone. In some embodiments, the reduction in expression level upon administration of a combination of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof may be at least about 25%, at least about 50%, at least about 75%, at least about 100%, at least about 125%, at least about 150%, at least about 175%, or at least about 200% greater than the reduction caused by administration of at least one MetAP2 inhibitor alone and / or at least one CDK4 / 6 inhibitor alone.
[0075] In some embodiments, administration of a combination of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof can result in a reduction in the expression level of at least one protein in at least one tumor of a target that would otherwise be caused by administration of at least one MetAP2 inhibitor alone and / or at least one CDK4 / 6 inhibitor alone. In some embodiments, the at least one protein may include Rb protein, p21 protein, CDK2 protein, CDK4 protein, cyclin E1 protein, cyclin E2 protein, LC3B protein, estrogen receptor, Akt protein, or any combination thereof. In some embodiments, the decline may be at least about 5%, or at least about 10%, or at least about 15%, or at least about 20%, or at least about 25%, or at least about 30%, or at least about 35%, or at least about 40%, or at least about 45%, or at least about 50%, or at least about 55%, or at least about 60%, or at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 99%.
[0076] In some embodiments, administration of a combination of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof can result in an increase in the expression of at least one small protein, which is smaller than the increase in expression levels caused by administration of at least one MetAP2 inhibitor alone and / or at least one CDK4 / 6 inhibitor alone. In some embodiments, the at least one protein may be p21, LC3B, or cyclin D1. In some embodiments, the increase in expression upon administration of a combination of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof is at least about 10%, at least about 25%, at least about 50%, at least about 75%, at least about 100%, at least about 125%, at least about 150%, at least about 175%, or 200% lower than the increase in expression upon administration of at least one MetAP2 inhibitor alone and / or at least one CDK4 / 6 inhibitor alone.
[0077] In some embodiments, administration of a combination of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof can attenuate the increase in expression of at least one protein compared to the increase in expression levels caused by administration of at least one MetAP2 inhibitor alone and / or at least one CDK4 / 6 inhibitor alone. In some embodiments, the at least one protein may be p21, Akt protein, or cyclin D1. In some embodiments, the attenuation may be at least about 10%, at least about 25%, at least about 50%, at least about 75%, or at least about 100%.
[0078] In some embodiments, administration of a combination of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof may result in an increase in the expression of at least one protein of about 10%, or about 20%, or about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90%, or about 100% or less.
[0079] In some embodiments, administration of a combination of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof may result in an increase in the neutrophil count in subjects compared to subjects administered with at least one MetAP2 inhibitor alone and / or at least one CDK4 / 6 inhibitor alone. In some embodiments, the amount of neutrophils in a subject administered a combination of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, or at least about 60% compared to the amount of neutrophils in a subject administered at least one MetAP2 inhibitor alone and / or at least one CDK4 / 6 inhibitor alone. Larger by %, or at least approximately 65%, or at least approximately 70%, or at least approximately 75%, or at least approximately 80%, or at least approximately 85%, or at least approximately 90%, or at least approximately 95%, or at least approximately 100%, or at least approximately 125%, or at least approximately 150%, or at least approximately 175%, or at least approximately 200%, or at least approximately 225%, or at least approximately 250%, or at least approximately 275%, or at least approximately 300%, or at least approximately 325%, or at least approximately 350%, or at least approximately 375%, or at least approximately 400%, or at least approximately 425%, or at least approximately 450%.
[0080] In some embodiments, administration of a combination of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof and at least one CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof may result in an increase in the expression level of at least one gene. In some embodiments, the at least one gene may include PIK3IP1, SCUBE2, and EVL. In some embodiments, the increase in the expression level of at least one protein may be at least about 5%, or at least about 10%, or at least about 15%, or at least about 20%, or at least about 25%, or at least about 30%, or at least about 35%, or at least about 40%, or at least about 45%, or at least about 50%, or at least about 55%, or at least about 60%, or at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 99%.
[0081] MetAP2 inhibitors
[0082] Any of the MetAP2 inhibitors described herein may be used in the kits, pharmaceutical compositions, uses, and methods described herein.
[0083] In some embodiments, the MetAP2 inhibitor may be a compound of formula (I) or a pharmaceutically acceptable salt, analogue, derivative, salt, or ester thereof, where formula I is [ka] Represented by the formula, where independently in each case, R4 is H or C1-C6 alkyl, R5 is H or C1-C6 alkyl, R6 is C2-C6 hydroxyalkyl, Z is -NH-AA1-AA2-AA3-AA4-AA5-AA6-C(O)-L or NH-AA1-AA2-AA3-AA4-AA5-AA6-C(O)-QXYC(O)-W, and AA1 is glycine, alanine, or H2N(CH2)m is CO2H, m is 2, 3, 4, or 5, AA2 is a bond, or alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, or tyrosine, AA3 is a bond, or alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, or tyrosine, AA4 is a bond, or alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, or tyrosine, AA5 is a bond, or glycine, valine, tyrosine, tryptophan, phenylalanine, methionine, leucine, isoleucine, or asparagine, AA6 is a bond, or alanine, leucine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine, or H2N(CH2) m is CO2H, m is 2, 3, 4, or 5, L is -OH, -O-succinimide, -O-sulfosuccinimide, alkoxy, aryloxy, acyloxy, aroyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, -NH2, -NH(C2-C6 hydroxyalkyl), halide, or perfluoroalkyloxy, Q is NR, O, or S, X is M-(C(R)2) p -M-J-M-(C(R)2) p -M-V, where M is a bond or C(O), J is a bond, or ((CH2) q Q) r , C5-C8 cycloalkyl, aryl, heteroaryl, NR, O, or S, Y is NR, O, or S, R is H or alkyl, V is a bond or [ka] And R9 is alkyl, aryl, aralkyl, or bonded, or R9 together with Y forms a heterocycle, R 10 is an amide or bond, R 11 is H or alkyl, W is a MetAP2 inhibitor moiety or alkyl, x is in the range of 1 to about 450, y is in the range of 1 to about 30, n is in the range of 1 to about 100, p is in the range of 0 to 20, q is 2 or 3, and r is 1, 2, 3, 4, 5, or 6. In some embodiments, n is in the range of about 1 to about 90, about 1 to about 80, about 1 to about 70, about 1 to about 60, about 1 to about 55, or about 1 to about 50.
[0084] In some embodiments, R4 is a C1-C6 alkyl group. In some embodiments, R4 is methyl. In some embodiments, R5 is a C1-C6 alkyl group. In some embodiments, R5 is methyl. In some embodiments, R6 is 2-hydroxyethyl, 2-hydroxypropyl, or 3-hydroxypropyl. In some embodiments, R6 is 2-hydroxypropyl.
[0085] In some embodiments, the compound has a molecular weight greater than about 100 kDa. In some embodiments, the compound has a molecular weight less than about 100 kDa. In some embodiments, the molecular weight is less than about 95 kDa. In some embodiments, the molecular weight is less than about 90 kDa. In some embodiments, the molecular weight is less than about 80 kDa. In some embodiments, the molecular weight is less than about 70 kDa. In some embodiments, the molecular weight is less than about 65 kDa. In some embodiments, the molecular weight is less than about 60 kDa. In some embodiments, the molecular weight is less than about 45 kDa. In some embodiments, the molecular weight is less than about 35 kDa.
[0086] In some embodiments, the ratio of x to y is in the range of about 100:1 to about 1:1. In some embodiments, the ratio of x to y is in the range of about 30:1 to about 3:1. In some embodiments, the ratio of x to y is in the range of about 19:2 to about 7:2. In some embodiments, the ratio of x to y is in the range of about 9:1 to about 4:1. In some embodiments, the ratio of x to y is about 11:1. In some embodiments, the ratio of x to y is about 9:1. In some embodiments, the ratio of x to y is about 4:1. In some embodiments, the ratio of x to y is about 12:1. For example, in some embodiments, the ratio of x:y is approximately 3:1, the ratio of x:y is approximately 4:1, the ratio of x:y is approximately 5:1, the ratio of x:y is approximately 6:1, the ratio of x:y is approximately 7:1, the ratio of x:y is approximately 8:1, the ratio of x:y is approximately 9:1, the ratio of x:y is approximately 10:1, the ratio of x:y is approximately 11:1, the ratio of x:y is approximately 12:1, the ratio of x:y is approximately 13:1, the ratio of x:y is approximately 14:1, the ratio of x:y is approximately 15:1, and the ratio of x:y is approximately 16:1. The ratio of x:y is approximately 17:1, the ratio of x:y is approximately 18:1, the ratio of x:y is approximately 19:1, the ratio of x:y is approximately 20:1, the ratio of x:y is approximately 21:1, the ratio of x:y is approximately 22:1, the ratio of x:y is approximately 23:1, the ratio of x:y is approximately 24:1, the ratio of x:y is approximately 25:1, the ratio of x:y is approximately 26:1, the ratio of x:y is approximately 27:1, the ratio of x:y is approximately 28:1, the ratio of x:y is approximately 29:1, or the ratio of x:y is approximately 30:1.
[0087] In some embodiments, Z is -NH-AA1-AA2-AA3-AA4-AA5-AA6-C(O)-L. In some embodiments, L is methoxy, ethoxy, pentafluorophenyloxy, phenyloxy, acetoxy, fluoride, chloride, methoxycarbonyloxy, ethoxycarbonyloxy, phenyloxycarbonyloxy, 4-nitrophenyloxy, trifluoromethoxy, pentafluoroethoxy, or trifluoroethoxy. In some embodiments, L is 4-nitrophenyloxy.
[0088] In some embodiments, Z is -NH-AA1-AA2-AA3-AA4-AA5-AA6-C(O)-QXYC(O)-W. In some embodiments, AA1 is glycine. In some embodiments, AA2 is glycine. In some embodiments, AA3 is glycine. In some embodiments, AA4 is glycine or phenylalanine. In some embodiments, AA5 is leucine, phenylalanine, valine, or tyrosine. In some embodiments, AA6 is asparagine, citrulline, glutamine, glycine, leucine, methionine, threonine, or tyrosine. In some embodiments, AA5-AA6 are Leu-Cit, Leu-Gln, Leu-Gly, Leu-Leu, Leu-Met, Leu-Thr, Phe-Cit, Phe-Gln, Phe-Leu, Phe-Met, Phe-Thr, Val-Asn, Val-Cit, Val-Gln, Val-Leu, Val-Met, Val-Thr, Tyr-Cit, Tyr-Leu, or Tyr-Met. In some embodiments, AA1, AA3, and AA5 are glycine, valine, tyrosine, tryptophan, phenylalanine, methionine, leucine, isoleucine, or asparagine. In some embodiments, AA2, AA4, and AA6 are glycine, asparagine, citrulline, glutamine, glycine, leucine, methionine, phenylalanine, threonine, or tyrosine. In some embodiments, AA2 is a bond, and AA3 is a bond. In some embodiments, AA1 is glycine, AA4 is phenylalanine, AA5 is leucine, and AA6 is glycine.
[0089] In some embodiments, W is [ka] [ka] [ka] [ka] [ka] In the formula, R2 is -OH or methoxy, and R3 is H, -OH, or methoxy.
[0090] In some embodiments, W is [ka] That is the case.
[0091] In some embodiments, W is [ka] That is the case.
[0092] In some embodiments, Q is NR. In some embodiments, Q is S.
[0093] In some embodiments, J is NR. In some embodiments, J is ((CH2) q Q) r In some embodiments, J is a C5-C8 cycloalkyl group. In some embodiments, J is an aryl group.
[0094] In some embodiments, Y is NR. In some embodiments, Y is S.
[0095] In some embodiments, -QXY- is [ka] [ka] And V is, [ka] or a combination, R 12is either H or Me, or R 12 R 14 Together with R, they form a piperidine ring. 11 is H or Me, and R 13 R 12 It binds to form a piperidine ring.
[0096] In some embodiments, -QXY- is [ka] That is the case.
[0097] In some embodiments, -QXY- is [ka] That is the case.
[0098] In some embodiments, -QXY- is [ka] That is the case.
[0099] In some embodiments, -QXY is [ka] That is the case.
[0100] In some embodiments, -QXY- is [ka] In some embodiments, -QXY- is [ka] That is the case.
[0101] In some embodiments, R4 and R5 are methyl, R6 is 2-hydroxypropyl, Z is -NH-AA1-AA2-AA3-AA4-AA5-AA6-C(O)-QXYC(O)-W, AA1 is glycine, AA2 is a bond, AA3 is a bond, AA4 is phenylalanine, AA5 is leucine, AA6 is glycine, and -QXY- is [ka] And W is, [ka] That is the case.
[0102] In some embodiments, R4 and R5 are methyl, R6 is 2-hydroxypropyl, Z is -NH-AA1-AA2-AA3-AA4-AA5-AA6-C(O)-QXYC(O)-W, AA1 is glycine, AA2 is a bond, AA3 is a bond, AA4 is phenylalanine, AA5 is leucine, AA6 is glycine, and -QXY- is [ka] And W is, [ka] That is the case.
[0103] In some embodiments, R4 and R5 are methyl, R6 is 2-hydroxypropyl, Z is -NH-AA1-AA2-AA3-AA4-AA5-AA6-C(O)-QXYC(O)-W, AA1 is glycine, AA2 is a bond, AA3 is a bond, AA4 is phenylalanine, AA5 is leucine, AA6 is glycine, and -QXY- is [ka] And W is,
Chem.
[0104] In some embodiments, R4 and R5 are methyl, R6 is 2-hydroxypropyl, Z is -NH-AA1-AA2-AA3-AA4-AA5-AA6-C(O)-Q-X-Y-C(O)-W, AA1 is glycine, AA2 is a bond, AA3 is a bond, AA4 is phenylalanine, AA5 is leucine, AA6 is glycine, -Q-X-Y- is
Chem.
Chem.
[0105] In some embodiments, -Q-X-Y- is a self-sacrificing linker that releases the MetAP2 inhibitor in the form of a carbamate derivative, as shown in the following scheme.
Chem.
[0106] Another aspect of the present disclosure provides a conjugate with a linker having the structure ZQXYC(O)-W, where in each case independently, Z is H2N-AA2-AA3-AA4-AA5-AA6-C(O)- or H, AA2 is a linkage or alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, or tyrosine, and AA3 is a linkage or alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine AA4 is bound to alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, or tyrosine; AA5 is bound to alanine, cysteine, glycine, isoleucine, leucine, methionine, phenylalanine, valine, tryptophan, or AA6 is bound to alanine, asparagine, citrulline, glutamine, glycine, leucine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine, or H2N(CH2) m CO2H, where m is 2, 3, 4, or 5, Q is NR, O, or S, and X is M-(C(R)2) p -MJM-(C(R)2) p -MV, where M is a bond or C(O), and J is a bond or ((CH2) q Q) r , C5-C8 cycloalkyl, aryl, heteroaryl, NR, O, or S, Y is NR, O, or S, R is H or alkyl, and V is bond or [ka] R9 is alkyl, aryl, aralkyl, or bond, or R9 together with Y to form a heterocycle, 10 is an amide or bond, R 11 is H or alkyl, W is the MetAP2 inhibitor moiety, p is 0 to 20, q is 2 or 3, and r is 1, 2, 3, 4, 5, or 6.
[0107] In some embodiments, Z is H2N-AA5-AA6-C(O)-. In some embodiments, AA5 is alanine, cysteine, glycine, isoleucine, leucine, methionine, phenylalanine, valine, tryptophan, or tyrosine, and AA6 is glycine. In some embodiments, AA5 is leucine and AA6 is glycine. In some embodiments, AA5 is valine and AA6 is glycine. In some embodiments, AA5 is phenylalanine and AA6 is glycine. In some embodiments, AA5 is glycine and AA6 is glycine. In some embodiments, AA5 is not valine.
[0108] In some embodiments, Z is H2N-AA3-AA4-AA5-AA6-C(O)-. In some embodiments, AA5 is alanine, cysteine, glycine, isoleucine, leucine, methionine, phenylalanine, valine, tryptophan, or tyrosine, and each of AA3, AA4, or AA6 is glycine. In some embodiments, AA5 is leucine, and each of AA3, AA4, or AA6 is glycine. In some embodiments, AA5 is valine, and each of AA3, AA4, or AA6 is glycine. In some embodiments, AA5 is phenylalanine, and each of AA3, AA4, or AA6 is glycine. In some embodiments, AA3 is glycine, AA4 is phenylalanine, AA5 is leucine, and AA6 is glycine. In some embodiments, each of AA3, AA4, AA5, and AA6 is glycine. In some embodiments, AA5 is not valine.
[0109] In some embodiments, Z is H. In some embodiments, Z is H2N-AA6-C(O)-. In some embodiments, AA6 is glycine.
[0110] In some embodiments, Q is NR. In some embodiments, M is a bond. In some embodiments, J is a bond. In some embodiments, Y is NR.
[0111] In some embodiments, W is
Chemical formula
Chemical formula
Chemical formula
Chemical formula
Chemical formula
[0112] In some embodiments, W is
Chemical formula
[0113] In some embodiments, W is
Chemical formula
[0114] In some embodiments, -Q-X-Y- is
Chemical formula
[0115] In some embodiments, Z is H2N-AA5-AA6-C(O)-, where AA5 is leucine, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0116] In some embodiments, Z is H2N-AA5-AA6-C(O)-, where AA5 is valine, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0117] In some embodiments, Z is H2N-AA5-AA6-C(O)-, AA5 is phenylalanine, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0118] In some embodiments, Z is H2N-AA5-AA6-C(O)-, AA5 is glycine, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0119] In some embodiments, Z is H2N-AA3-AA4-AA5-AA6-C(O)-, AA5 is leucine, each of AA3, AA4, or AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0120] In some embodiments, Z is H2N-AA3-AA4-AA5-AA6-C(O)-, AA5 is valine, each of AA3, AA4, or AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0121] In some embodiments, Z is H2N-AA3-AA4-AA5-AA6-C(O)-, AA5 is phenylalanine, each of AA3, AA4, or AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0122] In some embodiments, Z is H2N-AA3-AA4-AA5-AA6-C(O)-, AA3 is glycine, AA4 is phenylalanine, AA5 is leucine, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0123] In some embodiments, Z is H2N-AA3-AA4-AA5-AA6-C(O)-, where each of AA3, AA4, AA5, and AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0124] In some embodiments, Z is H2N-AA6-C(O)-, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0125] In some embodiments, Z is H, and QXY are [ka] And W is, [ka] That is the case.
[0126] In some embodiments, Z is H2N-AA5-AA6-C(O)-, where AA5 is leucine, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0127] In some embodiments, Z is H2N-AA5-AA6-C(O)-, where AA5 is valine, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0128] In some embodiments, Z is H2N-AA5-AA6-C(O)-, AA5 is phenylalanine, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0129] In some embodiments, Z is H2N-AA5-AA6-C(O)-, AA5 is glycine, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0130] In some embodiments, Z is H2N-AA3-AA4-AA5-AA6-C(O)-, AA5 is leucine, each of AA3, AA4, or AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0131] In some embodiments, Z is H2N-AA3-AA4-AA5-AA6-C(O)-, AA5 is valine, each of AA3, AA4, or AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0132] In some embodiments, Z is H2N-AA3-AA4-AA5-AA6-C(O)-, AA5 is phenylalanine, each of AA3, AA4, or AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0133] In some embodiments, Z is H2N-AA3-AA4-AA5-AA6-C(O)-, AA3 is glycine, AA4 is phenylalanine, AA5 is leucine, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0134] In some embodiments, Z is H2N-AA3-AA4-AA5-AA6-C(O)-, where each of AA3, AA4, AA5, and AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0135] In some embodiments, Z is H2N-AA6-C(O)-, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0136] In some embodiments, Z is H, and QXY are [ka] And W is, [ka] That is the case.
[0137] In some embodiments, Z is H2N-AA5-AA6-C(O)-, where AA5 is leucine, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0138] In some embodiments, Z is H2N-AA5-AA6-C(O)-, where AA5 is valine, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0139] In some embodiments, Z is H2N-AA5-AA6-C(O)-, AA5 is phenylalanine, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0140] In some embodiments, Z is H2N-AA5-AA6-C(O)-, AA5 is glycine, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0141] In some embodiments, Z is H2N-AA3-AA4-AA5-AA6-C(O)-, AA5 is leucine, each of AA3, AA4, or AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0142] In some embodiments, Z is H2N-AA3-AA4-AA5-AA6-C(O)-, AA5 is valine, each of AA3, AA4, or AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0143] In some embodiments, Z is H2N-AA3-AA4-AA5-AA6-C(O)-, AA5 is phenylalanine, each of AA3, AA4, or AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0144] In some embodiments, Z is H2N-AA3-AA4-AA5-AA6-C(O)-, AA3 is glycine, AA4 is phenylalanine, AA5 is leucine, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0145] In some embodiments, Z is H2N-AA3-AA4-AA5-AA6-C(O)-, where each of AA3, AA4, AA5, and AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0146] In some embodiments, Z is H2N-AA6-C(O)-, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0147] In some embodiments, Z is H, and QXY are [ka] And W is, [ka] That is the case.
[0148] In some embodiments, Z is H2N-AA5-AA6-C(O)-, AA5 is leucine, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0149] In some embodiments, Z is H2N-AA5-AA6-C(O)-, AA5 is valine, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0150] In some embodiments, Z is H2N-AA5-AA6-C(O)-, AA5 is phenylalanine, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0151] In some embodiments, Z is H2N-AA5-AA6-C(O)-, AA5 is glycine, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0152] In some embodiments, Z is H2N-AA3-AA4-AA5-AA6-C(O)-, AA5 is leucine, each of AA3, AA4, or AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0153] In some embodiments, Z is H2N-AA3-AA4-AA5-AA6-C(O)-, AA5 is valine, each of AA3, AA4, or AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0154] In some embodiments, Z is H2N-AA3-AA4-AA5-AA6-C(O)-, AA5 is phenylalanine, each of AA3, AA4, or AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0155] In some embodiments, Z is H2N-AA3-AA4-AA5-AA6-C(O)-, AA3 is glycine, AA4 is phenylalanine, AA5 is leucine, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0156] In some embodiments, Z is H2N-AA3-AA4-AA5-AA6-C(O)-, where each of AA3, AA4, AA5, and AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0157] In some embodiments, Z is H2N-AA6-C(O)-, AA6 is glycine, and QXY is [ka] And W is, [ka] That is the case.
[0158] In some embodiments, Z is H, and QXY are [ka] And W is, [ka] That is the case.
[0159] Other active moieties that may be modified for use in the conjugates of this disclosure include the following structures. [ka]
[0160] In some embodiments, the MetAP2 inhibitor may be a compound represented by one or more of the formulas listed in Table 1, or a pharmaceutically acceptable salt, analog, derivative, salt, or ester thereof: [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12] [Table 1-13] [Table 1-14] [Table 1-15] [Table 1-16] [Table 1-17] [Table 1-18] [Table 1-19] [Table 1-20] [Table 1-21] [Table 1-22] *In the formula, the polymer has the following structure: [ka] It has, preferably, the following structure: [ka] It holds.
[0161] In some embodiments, MetAP2 inhibitors are [ka] Or it may be a pharmaceutically acceptable salt, analog, derivative, salt, or ester thereof.
[0162] In some embodiments, MetAP2 inhibitors are [ka] Or it may be a pharmaceutically acceptable salt, analog, derivative, salt, or ester thereof.
[0163] In some embodiments, MetAP2 inhibitors are [ka] Or it may be a pharmaceutically acceptable salt, analog, derivative, salt, or ester thereof.
[0164] In some embodiments, MetAP2 inhibitors are [ka] Or it may be a pharmaceutically acceptable salt, analog, derivative, salt, or ester thereof.
[0165] In some embodiments, MetAP2 inhibitors are [ka] Or it may be a pharmaceutically acceptable salt, analog, derivative, salt, or ester thereof.
[0166] In some embodiments, MetAP2 inhibitors are [ka] Or it may be a pharmaceutically acceptable salt, analog, derivative, salt, or ester thereof.
[0167] In some embodiments, MetAP2 inhibitors are [ka] Or it may be a pharmaceutically acceptable salt, analog, derivative, salt, or ester thereof.
[0168] In some embodiments, MetAP2 inhibitors are [ka] Or it may be a pharmaceutically acceptable salt, analog, derivative, salt, or ester thereof.
[0169] In some embodiments, MetAP2 inhibitors are [ka] Or it may be a pharmaceutically acceptable salt, analog, derivative, salt, or ester thereof.
[0170] In some embodiments, the MetAP2 inhibitor is cis-(3aRS,9bRS)-7-(benzenesulfonylamino)-1,3a,4,9b-tetrahydro-2H-fl[2,3-c]chromen-6-carboxylic acid;cis-(3aRS,9bRS)-7-[2-(3-diethylaminopropyl)-4-fluorobenzenesulfonylamino]-1,3a,4,9b-tetrahydro-2H-fl[2,3-c]chromen-6-carboxylic acid;cis-(3aRS,9bRS)-7-[2-(3-{pyrrolidine-1-yl}propyl)-4-fluorobenzenesulfonylamino]-1,3a,4,9b-tetrahydro-2H-fl[2,3-c]chromen-6-carboxylic acid;cis-(3aRS,9bRS)-7 -[2-((Z)-3-diethylaminoprop-1-enyl)-4-fluorobenzenesulfonylamino]-1,3a,4,9b-tetrahydro-2H-fl[2,3-c]chromene-6-carboxylic acid;cis-(3aR,9bR)-7-[2-((Z)-3-diethylaminoprop-1-enyl)-4-fluorobenzenesulfonylamino]-1,3a,4,9b-tetrahydro-2H-fl[2,3-c]chromene-6-carboxylic acid;cis-(3aS,9bS)-7-[ 2-((Z)-3-diethylaminoprop-1-enyl)-4-fluorobenzenesulfonylamino]-1,3a,4,9b-tetrahydro-2H-fl[2,3-c]chromene-6-carboxylic acid;7-[2-((Z)-3-diethylaminoprop-1-enyl)-4-fluorobenzenesulfonylamino]-1,2-dihydrofl[2,3-c]quinoline-6-carboxylic acid formate;7-(benzenesulfonylamino))-1,2-dihydrofl[2,3-c]quinoline-6-carboxylic acid Formate; cis-(3aRS,9bRS)-7-[2-((Z)-3-diethylaminoprop-1-enyl)-4-fluorobenzenesulfonylamino]-1,2,3a,4,5,9b-hexahydrofl[2,3-c]quinoline-6-carboxylic acid; (1aRS,7bSR)-5-[2-((Z)-3-diethylaminoprop-1-enyl)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid;(1aR,7bS)-5-[2-((Z)-3-diethylaminoprop-1-enyl)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid;(1aS,7bR)-5-[2-((Z)-3-diethylaminoprop-1-enyl)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid;(1aRS,7bSR)-5-[2-((Z)-3-diethylaminoprop- 1-enyl)-4-fluorobenzenesulfonylamino]-7b-methyl-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid;(1aRS,7bSR)-5-[2-((E)-3-diethylaminoprop-1-enyl)-4-fluorobenzenesulfonylamino]-7b-methyl-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid;cis-(3aRS,9bRS)-7-[2-(4-dimethylamino-butylamino)-benzenesulfonylamino ]-1,3a,4,9b-tetrahydro-2H-fluoro[2,3-c]chromene-6-carboxylic acid;(1aR,7bS)-5-[2-(3-diethylaminopropyl)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid;(1aRS,7bSR)-5-[2-((Z)-3-diethylaminoprop-1-enyl)-4-fluorobenzenesulfonylamino]-1,1-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c ]chromene-4-carboxylic acid; (1aR,7bS)-5-[2-((Z)-3-diethylaminoprop-1-enyl)-4-fluorobenzene-sulfonylamino]-1,1-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aS,7bR)-5-[2-((Z)-3-diethylaminoprop-1-enyl)-4-fluorobenzene-sulfonylamino]-1,1-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid;(1aRS,7bSR)-5-[2((Z)-3-ethylaminoprop-1-enyl)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid;(1aR,7bS)-5-[2((Z)-3-ethylaminoprop-1-enyl)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid;(1aS,7bR)-5-[2((Z)-3-ethylaminoprop-1-enyl)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid;(1aS,7bR)-5-[2((Z)-3-ethylaminoprop-1-enyl)-4-fluoro Olobenzene-sulfonylamino]-1,1a,2,7b-tetrahydro-cyclopropa[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-{2[(Z)-3-(pyrrolidine-1-yl)prop-1-enyl]-4-fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydro-cyclopropa[c]chromen-4-carboxylic acid;(1aR,7bS)-5-{2[(Z)-3-(pyrrolidine-1-yl)prop-1-enyl]-4-fluorobenzenesulfonylamino}-1,1a,2,7b-Teto tetrahydrocyclopropa[c]chromen-4-carboxylic acid;(1aS,7bR)-5-{2[(Z)-3-(pyrroridine-1-yl)prop-1-enyl]-4-fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-[2-(3-dimethylaminopropylamino)benzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid;(1aR,7bS)-5-[2-(3-dimethylaminopropylamino)benzenesulfonylamino] [Tylaminopropylamino)benzene-sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aS,7bR)-5-[2-(3-dimethylaminopropyl-amino)benzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-[2-(4-dimethylaminobutylamino)benzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid;(1aR,7bS)-5-[2-(4-dimethylamino-butylamino)benzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aS,7bR)-5-[2-(4-dimethylaminobutylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-[2-(5-dimethylamino-pentylamino)benzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; ( (1aRS,7bSR)-5-{2[(Z)-3-(propan-2-yl)aminoprop-1-enyl]-4-fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-{2[(Z)-3-((S)-3-hydroxypyrrolidine-1-yl)aminoprop-1-enyl]-4-fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-{2[(Z)- 3-((R)-3-hydroxypyrrolidine-1-yl)aminoprop-1-enyl]-4-fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-[2((Z)-4-diethylaminobuto-1-enyl)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid;(1aR,7bS)-5-[2((Z)-4-diethylaminobuto-1-enyl)-4-fluorobenzenes [Fonyl-amino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid; (1aS,7bR)-5-[2((Z)-4-diethylaminobut-1-enyl)-4-fluorobenzenesulfonyl-amino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid; (1aRS,7bSR)-5-{2-[2-(4-ethylpiperazine-1-yl)-ethyl]-4-fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-{2[(Z)-3-(azetidine-1-yl)prop-1-enyl]-4-fluorobenzene-sulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-{2[(Z)-3-(3-hydroxyazetidine-1-yl)prop-1-enyl]-4-fluorobenzene-sulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromen-4-carboxylic acid;(1aRS,7bSR )-5-{2[(Z)-3-(azetidine-1-yl)propyl]-4-fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-[2((Z)-4-diethylaminobutyl)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-{2-[N-(4-dimethylaminobutyl)-N-methylamino]-benzene Sulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropane-[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-{2-[((S)-1-ethylpyrrolidine-3-ylcarbamoyl)-methyl]-4-fluorobenzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropane-[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-[2-(1-ethylazetidine-3-yl)-4-fluorobenzenesulfonylamino] dro-cyclopropa[c]chromen-4-carboxylic acid; (1aRS,7bSR)-5-{2-[((R)-1-ethylpyrrolidine-3-ylcarbamoyl)methyl]-4-fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid; (1aRS,7bSR)-5-{2-[2-(pyrrolidine-1-yl)-ethyl]-4-fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-[2-((R)-1-ethylpyrrolidine-3-ylmethyl)-4-fluorobenzenesulfonyl-amino]-1,1a,2,7b-tetrahydro-cyclopropa[c]chromen-4-carboxylic acid;(1aS,7bR)-5-[2-((R)-1-ethylpyrrolidine-3-ylmethyl)-4-fluorobenzenesulfonyl-amino]-1,1a,2,7b-tetrahydro-cyclopropa Pa[c]chromen-4-carboxylic acid;(1aR,7bS)-5-[2-((R)-1-ethylpyrrolidine-3-ylmethyl)-4-fluorobenzenesulfonyl-amino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-{2-[((S)-1-ethylpyrrolidine-2-yl)carbonyl-aminomethyl]-4-fluorobenzene-sulfo; Nylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-[2-(4-dimethylaminobutyrylamino)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-[2-((S)-1-ethyl-pyrrolidine-3-ylmethyl)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid;(1aR (S,7bSR)-5-[2-(3-dimethylaminopropylcarbamoyl)benzene-sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid; (1aRS,7bSR)-5-(2-{[N-((S)-1-ethyl-pyrrolidine-3-yl)-N-methylcarbamoyl]methyl}-4-fluorobenzenesulfonylamino)-1,1a,2,7b-tetrahydrocyclopropa-[c]chromen-4-carboxylic acid; (1aRS,7bSR)-5-(2-{[N-((R)-1-ethyl-pyrrolidine-3 (-yl)-N-methylcarbamoyl]methyl}-4-fluorobenzenesulfonylamino)-1,1a,2,7b-tetrahydrocyclopropane-[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-{2-[2-((S)-1-ethylpyrrolidine-2-yl)ethylamino]-benzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropane-[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-{2-[2-((R)-1-ethylpyrrolidine-2-yl)ethylamino]-benzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromen-4-carboxylic acid; (1aRS,7bSR)-5-[2-(3-N,N,-diethylaminopropylamino)benzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid; (1aRS,7bSR)-5-(2-{[((R)-1-ethylpyrrolidine-2-yl)carbonylamino]methyl}-4-fluorobenzenesulfonylamino)-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-{2-[(1-ethylazetidine-3-ylmethyl)amino]benzene-sulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid;(1aS,7bR)-5-[2-((Z)-3-diethylaminoprop-1-enyl)benzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid;(1aR,7bS)-5-[2-((Z)-3-diethylaminoprop-1-enyl)benzene [Sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-(2-{N-[((R)-1-ethylpyrrolidine-2-yl)carbonyl]-N-methylaminomethyl}-4-fluorobenzenesulfonylamino)-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-(2-{N-[((S)-1-ethylpyrrolidine-2-yl)carbonyl]-N-methylaminomethyl (1aRS,7bSR)-5-{2-((R)-1-ethylpyrrolidine-3-ylmethyl)amino}-1,1a,2,7b-tetrahydrocyclopropane[c]chromene-4-carboxylic acid;(1aRS,7bSR)-5-{2-((R)-1-ethylpyrrolidine-3-ylmethyl)amino]-benzenesulfonylamino}-1,1a,2,7b-tetra Hydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[((S)-1-ethylpyrrolidine-3-ylmethyl)amino]-benzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-[2-(4-ethyl-2-oxopiperazine-1-ylmethyl)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid;(1aRS,7bSR)-5-[2-(1-ethylpiperidine-4-ylmethyl)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa-[c]chromen-4-carboxylic acid; (1aRS,7bSR)-5-{2-[2-(1-ethylazetidine-3-yl)ethyl]-4-fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid; (1aRS,7bSR)-5-{2-[((S)-1-azabicyclo[2. 2.2]oct-3-yl)amino]benzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-{2-[((R)-1-azabicyclo-[2.2.2]oct-3-yl)amino]benzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-(2-{[((S)-1-ethylpyrrolidine-3-carbonyl)amino]methyl}-4-fluoro- (Benzenysulfonylamino)-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-{2-[2-((R)-1-ethylpyrrolidine-3-ylamino)ethyl]-4-fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-{2-[((R)-1-ethylpyrrolidine-3-yl)amino]-benzenesulfonylamino}-1,1a,2,7b-tetrahydro Rocyclopropa-[c]chromen-4-carboxylic acid; (1aRS,7bSR)-5-{2-[((S)-1-ethylpyrrolidine-3-yl)amino]-benzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromen-4-carboxylic acid; (1aRS,7bSR)-5-(2-{[((R)-1-ethylpyrrolidine-3-carbonyl)amino]-methyl)}-4-fluorobenzenesulfonylamino)-1,1a,2,7b-tetrahydrocyclopropa-[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-[2-((Z)-3-diethylamino-2-methylprop-1-enyl)-4-fluorobenzene-sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid; (1aRS,7bSR)-5-{2-[2-((R)-1-ethylpyrrolidine-3-yl)ethylamino]benzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa Per-[c]chromen-4-carboxylic acid;(1aRS,7bSR)-5-{2-[2-((S)-1-ethylpyrrolidine-3-yl)ethylamino]-benzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropane-[c]chromen-4-carboxylic acid;(1aR,7bS)-5-[2-((S)-1-ethylpyrrolidine-3-yloxymethyl)-4-fluorobenzenesulfonylamino]-1,1a,2 ,7b-tetrahydrocyclopropa-[c]chromen-4-carboxylic acid;(1aR,7bS)-5-[2-((R)-1-ethylpyrrolidine-3-yloxymethyl)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa-[c]chromen-4-carboxylic acid;(1aR,7bS)-5-[2-(1-ethylpiperidine-3-ylmethyl)-4-fluorobenzenesulfonylamino] ]-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-4-carboxylic acid; (1aR,7bS)-5-{2-[2-((R)-1-ethylpyrrolidine-2-yl)ethyl]-4-fluorobenzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromen-4-carboxylic acid, and their pharmaceutically acceptable salts, stereoisomers, esters, and prodrugs can be selected.
[0171] In some embodiments, MetAP2 inhibitors are [ka] [ka] Alternatively, a selection of pharmaceutically acceptable salts, analogs, derivatives, salts, or esters thereof may be used.
[0172] For the purposes of this disclosure, chemical elements are identified according to the inside cover of the Periodic Table of Elements, CAS edition, Handbook of Chemistry and Physics, 67th edition, 1986–1987.
[0173] The term "alkyl" refers to a fully saturated, branched or unbranched carbon chain (radical) having a specified number of carbon atoms, or up to 30 carbon atoms if not specified. For example, "lower alkyl" refers to alkyls having 1 to 10 carbon atoms, such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and octyl, as well as their positional isomers. Alkyls with 10 to 30 carbon atoms include decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicosyl, henicosyl, docosyl, tricosyl, and tetracosyl. In certain embodiments, linear or branched alkyls have 30 or fewer carbon atoms in their skeleton (for example, C1 to C1 for linear alkyls). 30 For branched chains, C3~C 30 ), more preferably having 20 or fewer carbon atoms. Similarly, certain cycloalkyls may have 3 to 10 carbon atoms in their ring structure, and may also contain 5, 6, or 7 carbon atoms in their ring structure.
[0174] Unless otherwise specified, the term "lower alkyl" as used herein means alkyl groups as defined above, but having 1 to 10 carbon atoms or 1 to 6 carbon atoms in their skeletal structure, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl. Similarly, "lower alkenyl" and "lower alkynyl" have similar chain lengths. Throughout this application, certain alkyl groups are lower alkyl groups. In certain embodiments, substituents referred to as alkyl groups herein are lower alkyl groups.
[0175] As used herein, the term "carbo-ring" refers to an aromatic or non-aromatic ring in which each atom of the ring is carbon.
[0176] As used herein, the term "aryl" includes five-membered, six-membered, and seven-membered monocyclic aromatic groups which may contain 0 to 4 heteroatoms, such as benzene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine. These aryl groups having heteroatoms in the ring structure are also referred to as "aryl heterocyclic" or "heteroaromatic." The aromatic ring may be substituted at one or more ring positions with substituents such as halogens, azides, alkyls, aralkyls, alkenyls, alkynyls, cycloalkyls, hydroxyls, alkoxyls, aminos, nitros, sulfhydryls, iminos, amides, phosphonates, phosphinates, carbonyls, carboxyls, silyls, ethers, alkylthios, sulfonyls, sulfonamides, ketones, aldehydes, esters, heterocyclyls, aromatic or heteroaromatic moieties, -CF3, -CN, etc. The term "aryl" also includes polycyclic ring systems having two or more cyclic rings (the rings are "fused rings") in which two or more carbon atoms are common to two adjacent rings (where at least one of the rings is aromatic, and the other cyclic rings may be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, and / or heterocyclyl).
[0177] An "alkenyl" refers to a branched or unbranched unsaturated carbon chain group having a specified number of carbon atoms, or up to 26 carbon atoms if no limit is specified. It has one or more double bonds in the group. Alkenyls with 6 to 26 carbon atoms include various isomers such as hexenyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodenyl, tridecenyl, tetradecenyl, pentadecenyl, hexadecenyl, heptadecenyl, octadecenyl, nonadecenyl, eicocenyl, heneicosoenyl, dococenyl, tricocenyl, and tetracocenyl, and the unsaturated bond can be located anywhere in the group and can take on a (Z) or (E) configuration with respect to the double bond.
[0178] The term "alkynyl" refers to a hydrocarbyl group that falls within the range of alkenyls but has one or more triple bonds in its group.
[0179] As used herein, the terms "alkoxyl" or "alkoxy" refer to alkyl groups to which an oxygen group is bonded, as defined below. Typical alkoxy groups include methoxy, ethoxy, propoxy, and tert-butoxy. An "ether" is two hydrocarbons covalently bonded by oxygen. Therefore, substituents on alkyl groups that make the alkyl an ether or mimic an alkoxy in this way include -O-alkyl, -O-alkenyl, -O-alkynyl, and -O-(CH2) m It can be expressed by one of the following -R1 (where m and R1 are described below).
[0180] The term "heterocyclyl" or "heterocyclic group" refers to a 3- to 10-membered ring structure, more preferably a 3- to 7-membered ring, in which the ring structure contains 1 to 4 heteroatoms. Heterocyclic rings can also be polycyclic. Heterocyclyl groups include, for example, thiophene, thianthrene, furan, pyran, isobenzofuran, chromene, xanthene, phenoxatiin, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indidine, isoindole, indazole, purine, quinoridine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, sinnoline, pteridine, carbazole, carborin, phenanthidine, acridine, pyrimidine, phenanthroline, phenazine, phenalsazine, phenothiazine, furazan, phenoxazine, pyrrolidine, oxolane, thiolan, oxazole, piperidine, piperazine, morpholine, lactone, azetidinone, and pyrrolidinone, as well as lactams, sultams, and sultones. The heterocycle can be substituted at one or more positions with substituents such as halogens, alkyls, aralkyls, alkenyls, alkynyls, cycloalkyls, hydroxyls, aminos, nitros, sulfhydryls, iminos, amides, phosphates, phosphonates, phosphinates, carbonyls, carboxyls, silyls, sulfamoyls, sulfinyls, ethers, alkylthios, sulfonyls, ketones, aldehydes, esters, heterocyclyls, aromatics, or heteroaromatic moieties, -CF3, -CN, etc.
[0181] The term "alkylthio" refers to an alkyl group as defined above, to which a sulfur group is bonded. In certain embodiments, the "alkylthio" portion is -(S)-alkyl, -(S)-alkenyl, -(S)-alkynyl, and (S)-(CH2) m It is represented by one of the -R1 (where m and R1 are defined below). Typical alkylthio groups include methylthio and ethylthio.
[0182] As used herein, the term "nitro" means -NO2, the term "halogen" means F, Cl, Br, or I, the term "sulfhydryl" means -SH, the term "hydroxyl" means -OH, and the term "sulfonyl" means -SO2-.
[0183] The terms "amine" and "amino" are recognized in the art and refer to both unsubstituted and substituted amines, and to the portion that can be represented, for example, by the following general formula: [ka]
[0184] In the formula, R3, R5, and R6 are each independently hydrogen, alkyl, alkenyl, and (CH2) m - Represents R1, or R3 and R5, together with the N atom to which they are bonded, form a heterocycle having 4 to 8 atoms in the ring structure, where R1 represents an alkenyl, aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl, and m is an integer in the range of 0 to 8. In certain embodiments, only one of R3 or R5 may be a carbonyl, for example, R3, R5, and nitrogen do not form an imide together. In certain embodiments, R3 and R5 (and optionally R6) each independently represent hydrogen, alkyl, alkenyl, or (CH2) m -Represents R1. Therefore, as used herein, the term “alkylamine” means the amine group defined above to which a substituted or unsubstituted alkyl is attached, i.e., at least one of R3 and R5 is an alkyl group. In certain embodiments, the amino group or alkylamine is basic, meaning that it has a pKa ≥ 7.00. The protonated form of these functional groups has a pKa greater than 7.00 with respect to water.
[0185] The term "carbonyl" (C(O)) is recognized in the art and includes a portion represented by the following general formula: [ka]
[0186] In the formula, X represents a bond, oxygen, or sulfur, and R7 represents hydrogen, alkyl, alkenyl, or -(CH2) m -R1 represents a pharmaceutically acceptable salt, and R8 is hydrogen, alkyl, alkenyl or (CH2) m -R1 represents the group, where m and R1 are as defined above. When X is oxygen and R7 or R8 is not hydrogen, the above formula represents an "ester". When X is oxygen and R7 is as defined above, this part is referred to herein as a carboxyl group, and in particular, when R7 is hydrogen, the above formula represents a "carboxylic acid". When X is oxygen and R8 is hydrogen, the above formula represents a "formate". In general, when the oxygen atom in the above formula is replaced with sulfur, the above formula represents a "thiocarbonyl" group. When X is sulfur and R7 or R8 is not hydrogen, the above formula represents a "thioester" group. When X is sulfur and R7 is hydrogen, the above formula represents a "thiocarboxylic acid" group. When X is sulfur and R8 is hydrogen, the above formula represents a "thioformate" group. On the other hand, when X is a bond and R7 is not hydrogen, the above formula represents a "ketone" group. When X is a bond and R7 is hydrogen, the above formula represents an "aldehyde" group.
[0187] As used herein, the term “substituted” is intended to include all permissible substituents of an organic compound. In broad embodiments, permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of an organic compound. Exemplary substituents include, for example, those described herein above. There are one or more permissible substituents for a given organic compound, and they may be the same or different. For the purposes of this disclosure, heteroatoms such as nitrogen may have hydrogen substituents and / or any permissible substituents of the organic compounds described herein that satisfy the valence of the heteroatom. This disclosure is not intended to be limited in any way by the permissible substituents of the organic compounds. It will be understood that “substituted” or “substituted with” implies an implicit condition that such substitution is subject to the permissible valences of the atom and substituent being substituted, and that the substitution results in a stable compound that does not spontaneously undergo transformation, such as rearrangement, cyclization, or elimination.
[0188] The term "sulfamoyl" is recognized in the relevant technical field and includes a portion that can be expressed by the following general formula: [ka]
[0189] In the formula, R3 and R5 are as defined above.
[0190] The term "sulfate" is recognized in the art and includes a portion that can be represented by the following general formula: [ka]
[0191] In the formula, R7 is as defined above.
[0192] The term "sulfamide" is recognized in the relevant technical field and includes a portion that can be represented by the following general formula: [ka]
[0193] In the formula, R2 and R4 are as defined above.
[0194] The term "sulfonate" is recognized in the relevant art and includes a portion that can be represented by the following general formula: [ka]
[0195] In the formula, R7 is an electron pair, hydrogen, alkyl, cycloalkyl, or aryl.
[0196] As used herein, the terms "sulfoxide" or "sulfinyl" include parts that can be represented by the following general formula: [ka]
[0197] In the formula, R 12 This is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aralkyl, or aryl.
[0198] Similar substitutions can be made to alkenyl and alkynyl groups to produce, for example, aminoalkenyls, aminoalkynyls, amidealkenyls, amidealkynyls, iminoalkenyls, iminoalkynyls, thioalkenyls, thioalkynyls, carbonyl-substituted alkenyls, or alkynyls.
[0199] When used herein, each expression, such as alkyl, m, n, etc., is intended to be independent of its definition elsewhere in any given structure if it appears more than once in that structure.
[0200] The term “amino acid” is intended to encompass all compounds containing both amino and acid functional groups, including amino acid analogs and derivatives, whether natural or synthetic. In certain embodiments, the amino acids contemplated in this disclosure are those naturally occurring amino acids found in proteins, or naturally occurring anabolic or catabolic products of such amino acids containing an amino group and a carboxyl group. Naturally occurring amino acids are identified by conventional three-letter and / or one-letter abbreviations corresponding to the proper names of the amino acids, according to the following list. These abbreviations are accepted in the field of peptides and are recommended by the IUPAC-IUB Committee in biochemical nomenclature.
[0201] The term “amino acid residue” means an amino acid. Generally, the abbreviations used herein to designate naturally occurring amino acids are based on the recommendations of the IUPAC-IUB Committee on Biochemical Nomenclature (see Biochemistry (1972) 11:1726–1732). For example, Met, Ile, Leu, Ala, and Gly represent the “residues” of methionine, isoleucine, leucine, alanine, and glycine, respectively. A residue is a group derived from the corresponding α-amino acid by removing the OH portion of the carboxyl group and the H portion of the α-amino group.
[0202] The term "amino acid side chain" is defined by KD Kopple, "Peptides and Amino Acids," WABenjamin Inc., New York and Amsterdam, 1966, pp. 2 and 33, as a portion of an amino acid residue excluding the backbone. Examples of such side chains for common amino acids include -CH2CH2SCH3 (side chain of methionine), -CH2(CH3)-CH2CH3 (side chain of isoleucine), -CH2CH(CH3)2 (side chain of leucine), or H- (side chain of glycine). These side chains are pendant-like structures attached to the Cα carbon of the backbone.
[0203] As used herein, the term "peptide" refers to a sequence of amino acid residues linked to one another by peptide bonds or modified peptide bonds. The term "peptide" is intended to encompass peptide analogs, peptide derivatives, peptide mimes, and peptide variants. The term "peptide" is understood to include peptides of any length. Peptide sequences described herein are written according to the generally accepted convention of having the N-terminal amino acid on the left and the C-terminal amino acid on the right (e.g., H2N-AA1-AA2-AA3-AA4-AA5)-AA6-CO2H).
[0204] Certain compounds in this disclosure may exist in specific geometric or stereoisomers. This disclosure intends to include all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (d)-isomers, (l)-isomers, racemic mixtures thereof, and other mixtures thereof, which fall within the scope of this disclosure. Additional chiral carbon atoms may be present in substituents such as alkyl groups. All such isomers and mixtures thereof are intended to be included in this disclosure. Any expression of a particular isomer is illustrative only (for example, the example of a trans isomer also includes a cis isomer).
[0205] For example, if a specific enantiomer of a compound of the present disclosure is desired, it may be prepared by asymmetric synthesis or by chiral auxiliary derivation, which involves separating the resulting diastereomer mixture and cleaving the auxiliary groups to provide the pure enantiomer of the choice. Alternatively, if the molecule contains a basic functional group such as amino or an acidic functional group such as carboxyl, a diastereomer salt may be formed using a suitable optically active acid or base, and the diastereomer formed thereafter may be divided by fractional crystallization or chromatographic means well known in the art, after which the pure enantiomer may be recovered.
[0206] As used herein, the term “substituted” means that any one or more hydrogen atoms on a given atom are replaced with a group selected from those shown, provided that the substitution does not exceed the normal valency of the given atom and that the substitution results in a stable compound. If the substituent is keto (i.e., =O), two hydrogen atoms on the atom are replaced. Keto substituents are not present in aromatic moieties. As used herein, a ring double bond is a double bond formed between two adjacent ring atoms (e.g., C=C, C=N, or N=N). “Stable compound” and “stable structure” mean a compound that is robust enough to withstand isolation from a reaction mixture to a useful purity and formulation into an effective therapeutic agent.
[0207] If it is shown that the bond to a substituent crosses a bond connecting two atoms in the ring, such substituent may be bonded to any atom in the ring. If substituents are enumerated without indicating the atoms to which they bond in the rest of the compound of a given formula, the substituent may be bonded via any atom in such formula. Combinations of substituents and / or variables are permitted, but only if such combinations result in a stable compound.
[0208] If any variable (e.g., R1) appears two or more times in any composition or formula of a compound, the definition in each case is independent of the definition in the other cases. Therefore, for example, if it is shown that a group is substituted with 0 to 2 R1 moieties, that group may be optionally substituted with up to 2 R1 moieties, and the R1 in each case is selected independently of the definition of R1. Furthermore, combinations of substituents and / or variables are also permitted, but only if such combinations result in a stable compound.
[0209] In this specification, the structural formulas of compounds, in some cases for convenience, represent specific isomers, but this disclosure includes any isomers, such as geometric isomers, optical isomers based on chiral carbons, stereoisomers, and tautomers. Furthermore, crystalline polymorphisms may exist in compounds represented by formulas. Note that any crystalline form, mixtures of crystalline forms, or their anhydrous or hydrated forms are within the scope of this disclosure. Furthermore, so-called metabolites produced by the in vivo degradation of the compounds of the present invention are also within the scope of the present invention.
[0210] "Isomers" refer to compounds that have the same molecular formula but differ in the arrangement of their atoms or the spatial configuration of their atoms. Isomers with different spatial configurations of atoms are called "stereoisomers." Stereoiomers that are not mirror images of each other are called "diastereoisomers," while stereoisomers that are mirror images of each other but cannot be superimposed are called "enantiomers" or, sometimes, optical isomers. Alternatively, a mixture containing equal amounts of individual enantiomers with opposite chiralities is called a "racemic mixture."
[0211] A carbon atom bonded to four non-identical substituents is called a "chiral center."
[0212] A "chiral isomer" refers to a compound having at least one chiral center. Compounds with two or more chiral centers may exist as individual diastereomers or as a mixture of diastereomers, referred to as a "diastereomer mixture." If one chiral center is present, the stereoisomer may be characterized by the absolute configuration (R or S) of that chiral center. Absolute configuration refers to the spatial arrangement of substituents attached to the chiral center. Substituents attached to the chiral center under consideration are ranked according to the Kahn-Ingold-Prelogue priority rule. (Cahn et al.,Angew.Chem.Inter.Edit.1966,5,385;errata 511;Cahn et al.,Angew.Chem.1966,78,413;Cahn and Ingold,J.Chem.Soc.1951(London),612;Cahn et al.,Experientia 1956, 12, 81; Cahn, J. Chem. Educ. 1964, 41, 116).
[0213] Geometric isomers are diastereomers that exist due to the hindrance of rotation around a double bond. These configurations are distinguished by prefixes such as cis and trans, or Z and E, according to the Kahn-Ingold-Prelogue order rule, indicating that the groups are on the same side or opposite side of the double bond in the molecule.
[0214] Furthermore, the structures and other compounds discussed in this disclosure include all of their atropic isomers. An "atropic isomer" is a type of stereoisomer in which the atoms of two isomers are arranged differently in space. Atropic isomers exist by restricted rotation caused by the obstruction of the rotation of large groups around a central bond. Such atropic isomers typically exist as a mixture, but as a result of recent advances in chromatography techniques, it has become possible to separate a mixture of two atropic isomers when selected.
[0215] A "tautomer" is one of two or more structural isomers that exist in equilibrium and can be readily converted from one isomer to another. This conversion involves the formal transfer of hydrogen atoms due to the switching of adjacent conjugated double bonds. Tautomers exist in solution as a mixture of sets of tautomers. In solid form, one tautomer is usually dominant. In solutions where tautomerization is possible, a chemical equilibrium of tautomers will be reached. The exact ratio of tautomers depends on several factors, including temperature, solvent, and pH. The concept of tautomers that can be interconverted by tautomerization is called tautomerism.
[0216] Of the various types of tautomerism that can occur, two are commonly observed. Keto-enol tautomerism involves the simultaneous transfer of electrons and hydrogen atoms. Ring chain tautomerism occurs when an aldehyde group (-CHO) in a sugar chain molecule reacts with one of the hydroxyl groups (-OH) in the same molecule, conferring the cyclic (ring-shaped) form characteristic of glucose to it.
[0217] Common tautomer pairs include ketone-enol, amide-nitrile, lactam-lactim, amide-imido acid tautomerism in heterocyclic structures (e.g., nucleic acid bases such as guanine, thymine, and cytosine), amine-enamine, and enamine-enamine.
[0218] It should be understood that the compounds of this disclosure may be described as different tautomers. If a compound has tautomer forms, all tautomer forms are intended to be included within the scope of this disclosure, and the naming of the compounds does not exclude any tautomer forms.
[0219] The terms "crystalline polymorphism," "polymorphism," or "crystalline form" refer to the crystalline structure in which a compound (or its salt or solvate) can crystallize in different crystalline packing configurations, all of which have the same elemental composition. Different crystalline forms typically have different X-ray diffraction patterns, infrared spectra, melting points, density hardness, crystal shape, optical and electrical properties, stability, and solubility. A particular crystalline form may become dominant due to the recrystallization solvent, crystallization rate, storage temperature, and other factors. Crystallographic polymorphisms of a compound can be prepared by crystallization under different conditions.
[0220] Furthermore, the compounds of this disclosure, for example, salts of the compounds, may exist in hydrated or unhydrated (anhydrous) forms, or as solvates with other solvent molecules. Non-limiting examples of hydrates include monohydrates, dihydrates, etc. Non-limiting examples of solvates include ethanol solvate, acetone solvate, etc.
[0221] A "solvate" refers to a solvation form containing a stoichiometric or non-stoichiometric amount of solvent. Some compounds tend to capture solvent molecules in a certain molar ratio in their crystalline solid state, and thus form solvates. When the solvent is water, the solvate formed is a hydrate; when the solvent is an alcohol, the solvate formed is an alcoholate. Hydrates are formed by a combination of one or more water molecules and one substance molecule, with water retaining its molecular state as H2O.
[0222] As used herein, the term “analog” refers to a compound that is structurally similar to another but has a slightly different composition (for example, by replacing one atom with an atom of a different element, or by the presence of a particular functional group, or by replacing one functional group with another). Thus, an analog is a compound that is similar or equivalent to a reference compound in function and appearance, but differs from the reference compound in structure or origin.
[0223] The term “derivative” as defined herein refers to a compound having a common core structure and being substituted with any of the groups described herein.
[0224] The term "biological equivalent" refers to a compound resulting from the exchange of an atom or group of atoms with another atom or group of atoms that is broadly similar. The purpose of biological equivalent substitution is to create a new compound that has similar biological properties to the parent compound. Biological equivalent substitution may be based on physicochemical or topological considerations. Examples of biological equivalents of carboxylic acids include, but are not limited to, acylsulfonimides, tetrazoles, sulfonates, and phosphonates. See, for example, Patani and LaVoie, Chem. Rev. 96, 3147-3176, 1996.
[0225] In some embodiments, MetAP2 inhibitors can be administered by subcutaneous injection (SC).
[0226] In some embodiments, MetAP2 inhibitors can be administered approximately every four days (Q4D).
[0227] In some embodiments, the MetAP2 inhibitor can be administered approximately once a day (QD), approximately once every two days (Q2D), approximately once every three days (Q3D), approximately once every four days (Q4D), approximately once every five days (Q5D), approximately once every six days (Q6D), approximately once every seven days (Q7D), approximately once every eight days (Q8D), approximately once every nine days (Q9D), approximately once every ten days (Q10D), approximately once every eleven days (Q11D), approximately once every twelve days (Q12D), approximately once every thirteen days (Q13D), approximately once every fourteen days (Q14D), or approximately once every fifteen days (Q15D). In some embodiments, the MetAP2 inhibitor can be administered approximately once every seven days (Q7D). In some embodiments, MetAP2 inhibitors may be administered approximately once every 14 days (Q14D).
[0228] In some embodiments, the MetAP2 inhibitor is approximately 1 mg / m². 2 , or approximately 2 mg / m² 2 , or approximately 3 mg / m² 2 , or approximately 4 mg / m² 2 , or approximately 5 mg / m²2 or about 6 mg / m 2 or about 7 mg / m 2 or about 8 mg / m 2 or about 9 mg / m 2 or about 10 mg / m 2 or about 11 mg / m 2 or about 12 mg / m 2 or about 13 mg / m 2 or about 14 mg / m 2 or about 15 mg / m 2 or about 16 mg / m 2 or about 17 mg / m 2 or about 18 mg / m 2 or about 19 mg / m 2 or about 20 mg / m 2 or about 21 mg / m 2 or about 22 mg / m 2 or about 23 mg / m 2 or about 24 mg / m 2 or about 25 mg / m 2 or about 26 mg / m 2 or about 27 mg / m 2 m2 or about 28 mg / m 2 or about 29 mg / m 2 or about 30 mg / m 2 or about 31 mg / m 2 or about 32 mg / m 2 or about 33 mg / m 2 or about 34 mg / m 2 or about 35 mg / m 2 or about 36 mg / m 2 or about 37 mg / m 2 or about 38 mg / m 2 or about 39 mg / m 2 or about 40 mg / m 2 or about 41 mg / m 2 or about 42 mg / m 2 or about 43 mg / m 2 or about 44 mg / m 2 or about 45 mg / m2 or about 46 mg / m 2 or about 47 mg / m 2 or about 48 mg / m 2 or about 49 mg / m 2 or about 50 mg / m 2 or about 51 mg / m 2 or about 52 mg / m 2 or about 53 mg / m 2 or about 54 mg / m 2 or about 55 mg / m 2 or about 56 mg / m 2 or about 57 mg / m 2 or about 58 mg / m 2 or about 59 mg / m 2 or about 60 mg / m 2 or about mg / m 2 or about 61 mg / m 2 or about 62 mg / m 2 or about 63 mg / m 2 or about 64 mg / m 2 or about 65 mg / m 2 or about 66 mg / m 2 or about 67 mg / m 2 or about 68 mg / m 2 or about 69 mg / m 2 or about 70 mg / m 2 or about 81 mg / m 2 or about 82 mg / m 2 or about 83 mg / m 2 or about 84 mg / m 2 or about 85 mg / m 2 or about 86 mg / m 2 or about 87 mg / m 2 or about 88 mg / m 2 or about 89 mg / m 2 or about 90 mg / m 2 or about 91 mg / m 2 or about 92 mg / m 2 or about 93 mg / m 2 or about 94 mg / m2 , or approximately 95 mg / m² 2 , or approximately 96 mg / m² 2 , or approximately 97 mg / m² 2 , or approximately 98 mg / m² 2 , or approximately 99 mg / m² 2 , or approximately 100 mg / m² 2 It can be administered in that amount.
[0229] In some embodiments, the MetAP2 inhibitor is approximately 49 mg / m². 2 It can be administered in the amount of [amount]. In some embodiments, the MetAP2 inhibitor is approximately 39 mg / m². 2 ~about 59mg / m 2 It can be administered in the amount of [amount]. In some embodiments, the MetAP2 inhibitor is approximately 44 mg / m². 2 ~about 54mg / m 2 It can be administered in that amount.
[0230] In some embodiments, the MetAP2 inhibitor is approximately 36 mg / m². 2 It can be administered in the amount of [amount]. In some embodiments, the MetAP2 inhibitor is administered at approximately 26 mg / m². 2 ~approximately 49 mg / m² 2 It can be administered in the amount of [amount]. In some embodiments, the MetAP2 inhibitor is approximately 31 mg / m². 2 ~about 65mg / m 2 It can be administered in that amount.
[0231] In some embodiments, the MetAP2 inhibitor is administered at approximately 65 mg / m². 2 It can be administered in the amount of [amount]. In some embodiments, the MetAP2 inhibitor is administered at approximately 55 mg / m². 2 ~about 75mg / m 2 It can be administered in the amount of [amount]. In some embodiments, the MetAP2 inhibitor is administered at approximately 60 mg / m². 2 ~about 70mg / m 2 It can be administered in that amount.
[0232] In some embodiments, the therapeutically effective dose of a metAP2 inhibitor is approximately 1 mg / m². 2, or approximately 2 mg / m² 2 , or approximately 3 mg / m² 2 , or approximately 4 mg / m² 2 , or approximately 5 mg / m² 2 , or approximately 6 mg / m² 2 , or approximately 7 mg / m² 2 , or approximately 8 mg / m² 2 , or approximately 9 mg / m² 2 , or approximately 10 mg / m² 2 , or approximately 11 mg / m² 2 , or approximately 12 mg / m² 2 , or approximately 13 mg / m² 2 , or approximately 14 mg / m² 2 , or approximately 15 mg / m² 2 , or approximately 16 mg / m² 2 , or approximately 17 mg / m² 2 , or approximately 18 mg / m² 2 , or approximately 19 mg / m² 2 , or approximately 20 mg / m² 2 , or approximately 21 mg / m² 2 , or approximately 22 mg / m² 2 , or approximately 23 mg / m² 2 , or approximately 24 mg / m² 2 , or approximately 25 mg / m² 2 , or approximately 26 mg / m² 2 , or approximately 27 mg / m² 2 , or approximately 28 mg / m² 2 , or approximately 29 mg / m² 2 , or approximately 30 mg / m² 2 , or approximately 31 mg / m² 2 , or approximately 32 mg / m² 2 , or approximately 33 mg / m² 2 , or approximately 34 mg / m² 2 , or approximately 35 mg / m² 2 , or approximately 36 mg / m² 2 , or approximately 37 mg / m² 2 , or approximately 38 mg / m² 2 , or approximately 39 mg / m² 2 , or approximately 40 mg / m² 2 , or approximately 41 mg / m² 2, or approximately 42 mg / m² 2 , or approximately 43 mg / m² 2 , or approximately 44 mg / m² 2 , or approximately 45 mg / m² 2 , or approximately 46 mg / m² 2 , or approximately 47 mg / m² 2 , or approximately 48 mg / m² 2 , or approximately 49 mg / m² 2 , or approximately 50 mg / m² 2 , or approximately 51 mg / m² 2 , or approximately 52 mg / m² 2 , or approximately 53 mg / m² 2 , or approximately 54 mg / m² 2 , or approximately 55 mg / m² 2 , or approximately 56 mg / m² 2 , or approximately 57 mg / m² 2 , or approximately 58 mg / m² 2 , or approximately 59 mg / m² 2 , or approximately 60 mg / m² 2 , or approximately mg / m² 2 , or approximately 61 mg / m² 2 , or approximately 62 mg / m² 2 , or approximately 63 mg / m² 2 , or approximately 64 mg / m² 2 , or approximately 65 mg / m² 2 , or approximately 66 mg / m² 2 , or approximately 67 mg / m² 2 , or approximately 68 mg / m² 2 , or approximately 69 mg / m² 2 , or approximately 70 mg / m² 2 , or approximately 81 mg / m² 2 , or approximately 82 mg / m² 2 , or approximately 83 mg / m² 2 , or approximately 84 mg / m² 2 , or approximately 85 mg / m² 2 , or approximately 86 mg / m² 2 , or approximately 87 mg / m² 2 , or approximately 88 mg / m² 2 , or approximately 89 mg / m² 2 , or approximately 90 mg / m² 2, or approximately 91 mg / m² 2 , or approximately 92 mg / m² 2 , or approximately 93 mg / m² 2 , or approximately 94 mg / m² 2 , or approximately 95 mg / m² 2 , or approximately 96 mg / m² 2 , or approximately 97 mg / m² 2 , or approximately 98 mg / m² 2 , or approximately 99 mg / m² 2 , or approximately 100 mg / m² 2 It could be in that quantity.
[0233] In some embodiments, the therapeutically effective dose of a metAP2 inhibitor is approximately 49 mg / m². 2 This may be the case. In some embodiments, the therapeutically effective dose of a MetAP2 inhibitor is approximately 39 mg / m². 2 ~about 59mg / m 2 This may be the case. In some embodiments, the therapeutically effective dose of a MetAP2 inhibitor is approximately 44 mg / m². 2 ~about 54mg / m 2 It is possible.
[0234] In some embodiments, the therapeutically effective dose of a metAP2 inhibitor is approximately 36 mg / m². 2 This may be the case. In some embodiments, the therapeutically effective dose of a MetAP2 inhibitor is approximately 26 mg / m². 2 ~approximately 49 mg / m² 2 This may be the case. In some embodiments, the therapeutically effective dose of a MetAP2 inhibitor is approximately 31 mg / m². 2 ~approximately 49 mg / m² 2 It is possible.
[0235] In some embodiments, the therapeutically effective dose of a metAP2 inhibitor is approximately 65 mg / m². 2 This may be the case. In some embodiments, the therapeutically effective dose of a MetAP2 inhibitor is approximately 55 mg / m². 2 ~about 75mg / m 2 This may be the case. In some embodiments, the therapeutically effective dose of a MetAP2 inhibitor is approximately 60 mg / m². 2 ~about 70mg / m 2 It is possible.
[0236] In some embodiments, the MetAP2 inhibitor may be administered in amounts of approximately 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, or 200 mg. In some embodiments, the MetAP2 inhibitor may be administered in amounts of approximately 80 mg. In some embodiments, the MetAP2 inhibitor may be administered in amounts of approximately 70 mg to 90 mg. In some embodiments, the MetAP2 inhibitor may be administered in amounts of approximately 75 mg to 85 mg.
[0237] In some embodiments, the therapeutically effective dose of a MetAP2 inhibitor may be approximately 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, or 100 mg. In some embodiments, the therapeutically effective dose of a MetAP2 inhibitor may be approximately 80 mg. In some embodiments, the therapeutically effective dose of a MetAP2 inhibitor may be approximately 70 mg to 90 mg. In some embodiments, the therapeutically effective dose of a MetAP2 inhibitor may be approximately 75 mg to 85 mg.
[0238] CDK4 / 6 inhibitors
[0239] As used herein, the term “CDK4 / 6 inhibitor” is used to refer to a compound that inhibits cyclin-dependent kinase CDK4 and / or cyclin-dependent kinase CDK6.
[0240] As is understood by those skilled in the art, CDK4 / 6 inhibitors have also been shown to inhibit cyclin-dependent kinase CDK2 in some cases. Therefore, as used herein, the term CDK4 / 6 inhibitor may also refer to compounds that inhibit cyclin-dependent kinase CDK4 and / or cyclin-dependent kinase CDK6 and / or cyclin-dependent kinase CDK2.
[0241] In some embodiments, CDK4 / 6 inhibitors include palbociclib, abemaciclib, ribociclib, trilaciclib, SHR-6390, FCN-437c, relociclib, milcilib, PF-06873600, XZP-3287, zotiraciclib, BEBT-209, BPI-16350, CS-3002, fadracilib, HS-10342, ON-123300, PF-0 The following compounds can be selected: 6842874, TQ-05510, BPI-1178, JS-101, NUV-422, AU-294, CCT-68127, ETH-155008, HEC-80797, JRP-890, JS-104, NEOS-518, PF-07104091, PF-07220060, RMC-4550, SRX-3177, VS-2370, and VS-2370. In some embodiments, the CDK4 / 6 inhibitor can be selected from any of the pharmaceutically acceptable salts of the aforementioned compounds.
[0242] In some embodiments, the CDK4 / 6 inhibitor may be palbociclib or a pharmaceutically acceptable salt thereof.
[0243] In some embodiments, palbociclib may be administered orally. In some embodiments, palbociclib may be administered once daily. In some embodiments, palbociclib may be administered in amounts of approximately 75 mg / day, or approximately 100 mg / day, or approximately 125 mg / day, or approximately 150 mg / day, or approximately 175 mg / day, or approximately 200 mg / day. In some embodiments, palbociclib may be administered in amounts of approximately 125 mg / day. In some embodiments, palbociclib may be administered in amounts of approximately 50 mg / day to approximately 150 mg / day, or approximately 75 mg / day to approximately 175 mg / day, or approximately 100 mg / day to approximately 200 mg / day, or approximately 125 mg / day to approximately 225 mg / day, or approximately 150 to approximately 250 mg / day. In some embodiments, palbociclib can be administered once daily for approximately 21 days, followed by a period of approximately 7 days without administration.
[0244] In some embodiments, the effective therapeutic dose of palbociclib may be approximately 75 mg / day, or approximately 100 mg / day, or approximately 125 mg / day, or approximately 150 mg / day, or approximately 175 mg / day, or approximately 200 mg / day. In some embodiments, the effective therapeutic dose of palbociclib may be approximately 125 mg / day. In some embodiments, the effective therapeutic dose of palbociclib may be approximately 50 mg / day to approximately 150 mg / day, or approximately 75 mg / day to approximately 175 mg / day, or approximately 100 mg / day to approximately 200 mg / day, or approximately 125 mg / day to approximately 225 mg / day, or approximately 150 to approximately 250 mg / day.
[0245] In some embodiments, the effective therapeutic dose of palbociclib may be approximately 75 mg, or approximately 100 mg, or approximately 125 mg, or approximately 150 mg, or approximately 175 mg, or approximately 200 mg. In some embodiments, the effective therapeutic dose of palbociclib may be approximately 125 mg. In some embodiments, the effective therapeutic dose of palbociclib may be approximately 50 mg to approximately 150 mg, or approximately 75 mg to approximately 175 mg, or approximately 100 mg to approximately 200 mg, or approximately 125 mg to approximately 225 mg, or approximately 150 mg to approximately 250 mg.
[0246] In some embodiments, the CDK4 / 6 inhibitor may be abemaciclib or a pharmaceutically acceptable salt thereof.
[0247] In some embodiments, abemaciclib may be administered orally. In some embodiments, abemaciclib may be administered twice daily. In some embodiments, abemaciclib may be administered in doses of approximately 75 mg twice daily (total of approximately 150 mg / day), approximately 100 mg twice daily (total of approximately 200 mg / day), or approximately 125 mg twice daily (total of approximately 250 mg / day), or approximately 150 mg twice daily (total of approximately 300 mg / day), or approximately 175 mg twice daily (total of approximately 350 mg / day), or approximately 200 mg twice daily (total of approximately 400 mg / day), or approximately 225 mg twice daily (total of approximately 450 mg / day). In some aspects, abemaciclib is administered at approximately 50 mg / day to approximately 150 mg / day, or approximately 75 mg / day to approximately 175 mg / day, or approximately 100 mg / day to approximately 200 mg / day, or approximately 125 mg / day to approximately 225 mg / day, or approximately 150 to approximately 250 mg / day, or approximately 175 mg / day to approximately 275 mg / day, or approximately 200 mg / day to approximately 300 mg / day, or approximately 225 mg / day to approximately 325 mg / day, or approximately 250 mg / day, or approximately 350 mg / day, or approximately 275 mg / day, or approximately 375 mg / day, or approximately 300 mg / day to approximately 400 mg / day, or approximately 325 It can be administered in amounts of mg / day to approximately 425 mg / day, or approximately 350 mg / day to approximately 450 mg / day, or approximately 375 mg / day to approximately 475 mg / day, or approximately 400 mg / day to approximately 500 mg / day, or approximately 425 mg / day to approximately 525 mg / day, or approximately 450 mg / day to approximately 550 mg / day, or approximately 475 mg / day to approximately 575 mg / day, or approximately 500 mg / day to approximately 600 mg / day, or approximately 525 mg / day to approximately 625 mg / day, or approximately 550 mg / day to approximately 650 mg / day, or approximately 575 mg / day to approximately 675 mg / day, or approximately 600 mg / day to approximately 700 mg / day.
[0248] In some embodiments, the therapeutically effective dose of abemaciclib may be approximately 75 mg / day, or approximately 100 mg / day, or approximately 125 mg / day, or approximately 150 mg / day, or approximately 175 mg / day, or approximately 200 mg / day, or approximately 225 mg / day, or approximately 250 mg / day, or approximately 275 mg / day, or approximately 300 mg / day, or approximately 325 mg / day, or approximately 350 mg / day, or approximately 375 mg / day, or approximately 400 mg / day, or approximately 425 mg / day, or approximately 450 mg / day, or approximately 475 mg / day, or approximately 500 mg / day. In some embodiments, the effective therapeutic dose of abemaciclib is approximately 50 mg / day to approximately 150 mg / day, or approximately 75 mg / day to approximately 175 mg / day, or approximately 100 mg / day to approximately 200 mg / day, or approximately 125 mg / day to approximately 225 mg / day, or approximately 150 to approximately 250 mg / day, or approximately 175 mg / day to approximately 275 mg / day, or approximately 200 mg / day to approximately 300 mg / day, or approximately 225 mg / day to approximately 325 mg / day, or approximately 250 mg / day, or approximately 350 mg / day, or approximately 275 mg / day, or approximately 375 mg / day, or approximately 300 mg / day to approximately 400 mg / day. Alternatively, the dosage could be approximately 325 mg / day to approximately 425 mg / day, or approximately 350 mg / day to approximately 450 mg / day, or approximately 375 mg / day to approximately 475 mg / day, or approximately 400 mg / day to approximately 500 mg / day, or approximately 425 mg / day to approximately 525 mg / day, or approximately 450 mg / day to approximately 550 mg / day, or approximately 475 mg / day to approximately 575 mg / day, or approximately 500 mg / day to approximately 600 mg / day, or approximately 525 mg / day to approximately 625 mg / day, or approximately 550 mg / day to approximately 650 mg / day, or approximately 575 mg / day to approximately 675 mg / day, or approximately 600 mg / day or approximately 700 mg / day.
[0249] In some embodiments, the therapeutically effective dose of abemaciclib may be approximately 75 mg, or approximately 100 mg, or approximately 125 mg, or approximately 150 mg, or approximately 175 mg, or approximately 200 mg, or approximately 225 mg, or approximately 250 mg, or approximately 275 mg, or approximately 300 mg, or approximately 325 mg, or approximately 350 mg, or approximately 375 mg, or approximately 400 mg, or approximately 425 mg, or approximately 450 mg, or approximately 475 mg, or approximately 500 mg. In some embodiments, the effective therapeutic dose of abemaciclib is approximately 50 mg to 150 mg, or approximately 75 mg to 175 mg, or approximately 100 mg to 200 mg, or approximately 125 mg to 225 mg, or approximately 150 to 250 mg, or approximately 175 mg to 275 mg, or approximately 200 mg to 300 mg, or approximately 225 mg to 325 mg, or approximately 250 mg to 350 mg, or approximately 275 mg to 375 mg, or approximately 300 mg to 400 mg, or The amount may be approximately 325mg to 425mg, or approximately 350mg to 450mg, or approximately 375mg to 475mg, or approximately 400mg to 500mg, or approximately 425mg to 525mg, or approximately 450mg to 550mg, or approximately 475mg to 575mg, or approximately 500mg to 600mg, or approximately 525mg to 625mg, or approximately 550mg to 650mg, or approximately 575mg to 675mg, or approximately 600mg to 700mg.
[0250] In some embodiments, the CDK4 / 6 inhibitor may be ribociclib or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutically acceptable salt may be ribociclib succinate.
[0251] In some embodiments, ribociclib may be administered orally. In some embodiments, ribociclib may be administered once daily. In some embodiments, ribociclib may be administered in amounts of approximately 100 mg / day, or approximately 200 mg / day, or approximately 300 mg / day, or approximately 400 mg / day, or approximately 500 mg / day, or approximately 600 mg / day, or approximately 700 mg / day. In some embodiments, ribociclib may be administered in amounts of approximately 600 mg / day. In some embodiments, ribociclib is administered at approximately 50 mg / day to approximately 150 mg / day, or approximately 75 mg / day to approximately 175 mg / day, or approximately 100 mg / day to approximately 200 mg / day, or approximately 125 mg / day to approximately 225 mg / day, or approximately 150 to approximately 250 mg / day, or approximately 175 mg / day to approximately 275 mg / day, or approximately 200 mg / day to approximately 300 mg / day, or approximately 225 mg / day to approximately 325 mg / day, or approximately 250 mg / day, or approximately 350 mg / day, or approximately 275 mg / day, or approximately 375 mg / day, or approximately 300 mg / day to approximately 400 mg / day, or approximately 325 mg Palbociclib can be administered in doses of approximately 425 mg / day, or approximately 350 mg / day to approximately 450 mg / day, or approximately 375 mg / day to approximately 475 mg / day, or approximately 400 mg / day to approximately 500 mg / day, or approximately 425 mg / day to approximately 525 mg / day, or approximately 450 mg / day to approximately 550 mg / day, or approximately 475 mg / day to approximately 575 mg / day, or approximately 500 mg / day to approximately 600 mg / day, or approximately 525 mg / day to approximately 625 mg / day, or approximately 550 mg / day to approximately 650 mg / day, or approximately 575 mg / day to approximately 675 mg / day, or approximately 600 mg / day to approximately 700 mg / day. In some embodiments, palbociclib can be administered once daily for approximately 21 days, followed by a period of approximately 7 days without administration.
[0252] In some embodiments, the effective therapeutic dose of ribociclib may be approximately 100 mg / day, or approximately 200 mg / day, or approximately 300 mg / day, or approximately 400 mg / day, or approximately 500 mg / day, or approximately 600 mg / day, or approximately 700 mg / day. In some embodiments, the effective therapeutic dose of ribociclib may be approximately 600 mg / day. In some embodiments, the therapeutically effective dose of ribociclib is approximately 50 mg / day to approximately 150 mg / day, or approximately 75 mg / day to approximately 175 mg / day, or approximately 100 mg / day to approximately 200 mg / day, or approximately 125 mg / day to approximately 225 mg / day, or approximately 150 to approximately 250 mg / day, or approximately 175 mg / day to approximately 275 mg / day, or approximately 200 mg / day to approximately 300 mg / day, or approximately 225 mg / day to approximately 325 mg / day, or approximately 250 mg / day, or approximately 350 mg / day, or approximately 275 mg / day, or approximately 375 mg / day, or approximately 300 mg / day to approximately 400 mg / day, if The dosage may be approximately 325 mg / day to approximately 425 mg / day, or approximately 350 mg / day to approximately 450 mg / day, or approximately 375 mg / day to approximately 475 mg / day, or approximately 400 mg / day to approximately 500 mg / day, or approximately 425 mg / day to approximately 525 mg / day, or approximately 450 mg / day to approximately 550 mg / day, or approximately 475 mg / day to approximately 575 mg / day, or approximately 500 mg / day to approximately 600 mg / day, or approximately 525 mg / day to approximately 625 mg / day, or approximately 550 mg / day to approximately 650 mg / day, or approximately 575 mg / day to approximately 675 mg / day, or approximately 600 mg / day to approximately 700 mg / day.
[0253] In some embodiments, the effective therapeutic dose of ribociclib may be approximately 100 mg, or approximately 200 mg, or approximately 300 mg, or approximately 400 mg, or approximately 500 mg, or approximately 600 mg, or approximately 700 mg. In some embodiments, the effective therapeutic dose of ribociclib may be approximately 600 mg. In some embodiments, the effective therapeutic dose of ribociclib may be approximately 50 mg to approximately 150 mg, or approximately 75 mg to approximately 175 mg, or approximately 100 mg to approximately 200 mg, or approximately 125 mg to approximately 225 mg, or approximately 150 mg to approximately 250 mg, or approximately 175 mg to approximately 275 mg, or approximately 200 mg to approximately 300 mg, or approximately 225 mg to approximately 325 mg, or approximately 250 mg, or approximately 350 mg, or approximately 275 mg, or approximately 375 mg, or approximately 300 mg to approximately 400 mg. It may be g, or approximately 325 mg to 425 mg, or approximately 350 mg to 450 mg, or approximately 375 mg to 475 mg, or approximately 400 mg to 500 mg, or approximately 425 mg to 525 mg, or approximately 450 mg to 550 mg, or approximately 475 mg to 575 mg, or approximately 500 mg to 600 mg, or approximately 525 mg to 625 mg, or approximately 550 mg to 650 mg, or approximately 575 mg to 675 mg, or approximately 600 mg to 700 mg.
[0254] Several CDK4 / 6 inhibitors can be administered in conjunction with at least one additional therapeutic agent. Therefore, the compositions of the present disclosure may include a combination of at least one MetAP2 inhibitor, at least one CDK4 / 6 inhibitor, and at least one additional therapeutic agent.
[0255] In some embodiments, at least one additional therapeutic agent may include hormone therapy.
[0256] In some embodiments, at least one additional therapeutic agent may include an aromatase inhibitor. In some embodiments, the aromatase inhibitor may include a nonsteroidal aromatase inhibitor.
[0257] In some embodiments, the aromatase inhibitor may include anastrozole, exemestane, letrozole, or any combination thereof.
[0258] In some embodiments, at least one additional therapeutic agent may include a selective estrogen receptor degrader (SERD). In some embodiments, the SERD may include fulvestrant.
[0259] In some embodiments, at least one additional therapeutic agent may include a gonadotropin-releasing hormone agonist. In some embodiments, the gonadotropin-releasing hormone agonist may include goserelin.
[0260] In some embodiments, at least one additional therapeutic agent may include a PI3K inhibitor, an AKT inhibitor, an mTOR inhibitor, or a PI3K / Akt / mTOR pathway inhibitor.
[0261] In some embodiments, at least one additional therapeutic agent is therapelicib (TAK-117), BYL-719, AZD5363 (capavacertib), ipaserativeb (GDC0068), (paclitaxel + sirolimus + tanespimycin), (paclitaxel + sirolimus + tanespimycin), A-443654, AB-610, ACP-2127, ADC-0008830, AE-116, AEZS-126, AEZS-127, afresertib + trametinib, AL-58203, AL-58805, AL-58922, ALM-301, AP -185, AP-23675, AP-23841, Apitricib, ARQ-751, ASP-7486, AST-0669, AT-104, AT-13148, AUM-302, AZD-3147, AZD-8055, AZD-8154, BAY-1001931, BAY-1125976, BAY-1125976, BGT-226, Vimiralicib, BN-107, BN-108, Borcertiveb, Buformin, BVD-723, Capivacertiveb, CC-115, CC-2141, CC-2142, Certican ODT, CL-27, COTI-2, CT -365, Dactricib Tosylate, DC-120, DHM-25, Dihydroartemisinin, DS-3078, DS-7423, Dubellisib, EM-101, Everolimus, FP-208, FT-1518, FXY-1, Galarum, GDC-0349, Gedatricib, GM-6, GNE-317, GNE-555, GSK-690693, GT-0486, HD-148 series, HEC-68498, HM-032, HM-5016699, HMPL-518, Ipatasertib, IPI-549, ISC-4, J-9, JRP-890, KIT -2014, KS-99, LD-101, Lithium carbonate, LY-2503029, LY-2780301, M-2698, ME-344, Mirancertib mesylate, MK-2206, MKC-1, Monetpanthel, NISC-6, nPT-mTOR, NSC-765844, NV-128, Onatacertib, ONC-201, ONC-222, ONC-235, OSU-53, OT-043, OT-043, P-7170, P-7170, PBD-1226, Perifosine, PF-04691502, Pimasertib hydrochloride + voctalisib, PKI-179,PQR-311, PQR-316, PQR-401, PQR-4XX, PQR-514, PQR-530, PQR-620, PWT-33597, PX-316, Resilisib sodium, RES-529, Ridaforolimus, RMC-5552, RP-6503, RV-1729, RX-0183, RX-0201, RX-0201N, RX-0301, RX-1792, RX- 8243, samotricib, sapanicertib, SB-2602, SCC-31, SF-1126, SF-2523, SN-202, SPR-965, SR-13668, STP-503, SX-MTR1, TAFA-93, TAM-01, TAM-03, TAS-117, TASP-0415914, TE-7105, temsirolimus, tenalisib, TOP-216, trametinib This may include dimethyl sulfoxide + uprosertib, trisilibine phosphate, UB-1201, uprosertib, VCC-405567, VCC-668662, vistusertive, VLI-27, voxtalisib, VS-5584, WX-008, WXFL-10030390, X-387, X-414, X-480, XL-388, XL-418, XP-105, Y-31, Zoltress, or any combination thereof.
[0262] Targets of treatment and cancer
[0263] In some embodiments, the subject requiring it is an animal. In some embodiments, the animal may be a mammal. In some embodiments, the subject requiring it is a human being.
[0264] In some embodiments, the person requiring it is a person aged 18 or older. In some embodiments, the person requiring it is a person under the age of 18.
[0265] In some embodiments, the subject requiring it has cancer. In some embodiments, the cancer is characterized by at least one tumor present in the subject.
[0266] The terms “cancer” and “malignant” refer to or describe a physiological condition in mammals typically characterized by uncontrolled cell proliferation. This definition includes both benign and malignant cancers. Examples of cancers include, but are not limited to, carcinomas, lymphomas, blastomas, sarcomas, leukemias, and germ cell tumors. More specific examples of such cancers include adrenocortical carcinoma, urothelial carcinoma of the bladder, invasive breast carcinoma, squamous cell carcinoma of the cervix, intracervical adenocarcinoma, cholangiocarcinoma, colon adenocarcinoma, lymphoid neoplasm diffuse large B-cell lymphoma, esophageal cancer, glioblastoma multiforme, squamous cell carcinoma of the head and neck, chromophobic renal cancer, clear cell carcinoma of the kidney, papillary cell carcinoma of the kidney, acute myeloid leukemia, low-grade glioma of the brain, hepatocellular carcinoma of the liver, adenocarcinoma of the lung, squamous cell carcinoma of the lung, mesothelioma, serous cystadenocarcinoma of the ovary, adenocarcinoma of the pancreas, pheochromocytoma, paraganglioma, adenocarcinoma of the prostate, adenocarcinoma of the rectum, sarcoma, cutaneous melanoma, gastric adenocarcinoma, germ cell tumor of the testis, thyroid cancer, thymoma, carcinosarcoma of the uterus, and uveal melanoma. Other examples include breast cancer, lung cancer, lymphoma, melanoma, liver cancer, colorectal cancer, ovarian cancer, bladder cancer, kidney cancer, or stomach cancer.Further examples of cancer include neuroendocrine cancer, non-small cell lung cancer (NSCLC), small cell lung cancer, thyroid cancer, endometrial cancer, bile duct cancer, esophageal cancer, anal cancer, salivary cancer, vulvar cancer, cervical cancer, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), adrenal tumors, anal cancer, bile duct cancer, bladder cancer, bone cancer, intestinal cancer, brain tumor, breast cancer, cancer of unknown primary origin (CUP), cancer that has spread to the bone, cancer that has spread to the brain, cancer that has spread to the liver, cancer that has spread to the lungs, carcinoid cancer, cervical cancer, childhood cancer, chromolomycetic leukemia (CLL), chronic myeloid leukemia (CML), colorectal cancer, ear cancer, endometrial cancer, eye cancer, follicular dendritic cell sarcoma, gallbladder cancer, and gastric cancer. Cancer, esophagogastric junction cancer, germ cell tumors, gestational trophoblastic disease (GIT), hairy cell leukemia, head and neck cancer, Hodgkin lymphoma, Kaposi's sarcoma, kidney cancer, laryngeal cancer, leukemia, scirrhous gastric cancer, liver cancer, lung cancer, lymphoma, malignant schwannoma, mediastinal germ cell tumor, melanoma, male cancer, Merkel cell carcinoma, mesothelioma, molar pregnancy, oral and oropharyngeal cancer, myeloma, nasal and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, neuroendocrine tumors, non-Hodgkin lymphoma (NHL), esophageal cancer, ovarian cancer, pancreatic cancer, penile cancer, persistent choriocarcinoma and choriocarcinoma, pheochromocytoma, prostate cancer, pseudomyxoma peritonei, rectal cancer, retinoblastoma, salivary gland cancer, secondary cancer, signet ring cell carcinoma, skin cancer, small intestine cancer, soft tissue sarcoma, stomach cancer This includes, but is not limited to, cancer, T-cell pediatric non-Hodgkin lymphoma (NHL), testicular cancer, thymic cancer, thyroid cancer, tongue cancer, tonsil cancer, adrenal tumors, uterine cancer, vaginal cancer, vulvar cancer, Wilms' tumor, womb cancer, and gynecological cancers.Examples of cancer include, but are not limited to, hematological malignancies, lymphomas, cutaneous T-cell lymphomas, peripheral T-cell lymphomas, Hodgkin lymphomas, non-Hodgkin lymphomas, multiple myeloma, chromlympholyxic leukemia, chronic myeloid leukemia, myelodysplastic syndromes, myelofibrosis, biliary tract cancers, hepatocellular carcinomas, colorectal cancers, breast cancers, lung cancers, non-small cell lung cancers, ovarian cancers, thyroid cancers, renal cell carcinomas, pancreatic cancers, bladder cancers, skin cancers, malignant melanomas, Merkel cell carcinomas, uveal melanomas, or glioblastoma multiforme.
[0267] In some embodiments, cancer is carcinoma, lymphoma, blastoma, sarcoma, leukemia, brain tumor, breast cancer, blood cancer, bone cancer, lung cancer, skin cancer, liver cancer, ovarian cancer, bladder cancer, kidney cancer, renal cancer, gastric cancer, thyroid cancer, pancreatic cancer, esophageal cancer, prostate cancer, cervical cancer, uterine cancer, stomach cancer, soft tissue cancer, laryngeal cancer, small intestine cancer, testicular cancer, anal cancer, vulvar cancer, joint cancer, oral cancer, pharyngeal cancer, or colorectal cancer.
[0268] In some aspects, cancer is breast cancer.
[0269] In some embodiments, breast cancer is metastatic breast cancer. As used herein, metastatic breast cancer is stage III or IV breast cancer that has spread to other parts of the body, including but not limited to the liver, brain, and bones.
[0270] In some embodiments, breast cancer is human epidermal growth factor 2 (HER2) negative breast cancer.
[0271] In some forms, breast cancer is HR+HER2- breast cancer.
[0272] In some embodiments, breast cancer may be luminal A breast cancer. In some embodiments, breast cancer may be luminal B breast cancer. In some embodiments, breast cancer may be triple-negative or basal-like breast cancer. In some embodiments, breast cancer may be HER2-enriched breast cancer.
[0273] In some aspects, the cancer is head and neck cancer.
[0274] In some cases, the cancer is non-small cell lung cancer.
[0275] In some embodiments, cancer is a brain tumor. In some embodiments, a brain tumor may be a recurrent brain metastasis.
[0276] In some aspects, the cancer is squamous cell carcinoma.
[0277] In some aspects, cancer is a tumor of the central nervous system.
[0278] In some aspects, the cancer is a liposarcoma.
[0279] In some aspects, the cancer is endometrial cancer.
[0280] In some aspects, cancer is a neuroendocrine tumor.
[0281] In some cases, the cancer is small cell lung cancer (SCLC).
[0282] General definition
[0283] It should be understood that the compounds of this disclosure may be expressed as different tautomers. Where a compound has tautomer forms, all tautomer forms are intended to be included within the scope of this disclosure, and no tautomer forms are excluded by the naming of the compound. It should also be understood that certain tautomers may have higher activity levels than others.
[0284] As used herein, the terms “crystalline polymorphism,” “polymorphism,” or “crystalline form” mean that a compound (or its salt or solvate) can crystallize in different crystalline packing configurations, all of which have the same elemental composition. Different crystalline forms typically have different X-ray diffraction patterns, infrared spectra, melting points, density hardness, crystal shape, optical and electrical properties, stability, and solubility. A particular crystalline form may become dominant due to the recrystallization solvent, crystallization rate, storage temperature, and other factors. Crystallographic polymorphisms of a compound can be prepared by crystallization under different conditions.
[0285] It should be understood that any compound of any formula described herein includes the compound itself, as well as its salts and, where applicable, its solvates. For example, salts may be formed between an anion on a substituted benzene compound and a positively charged group (e.g., amino). Suitable anions include chlorides, bromides, iodides, sulfates, bisulfates, sulfamates, nitrates, phosphates, citrates, methanesulfons, trifluoroacetates, glutamates, glucurons, glutarates, malates, maleates, succinates, fumarates, tartrates, tosylates, salicylates, lactates, naphthalenesulfons, and acetates (e.g., trifluoroacetates).
[0286] As used herein, the term “pharmaceutically acceptable anion” refers to an anion suitable for forming a pharmaceutically acceptable salt. Similarly, salts can also be formed between a cation on a substituted benzene compound and a negatively charged group (e.g., a carboxylate salt). Suitable cations include sodium, potassium, magnesium, calcium, and ammonium cations such as the tetramethylammonium ion. Substituted benzene compounds also include salts containing a quaternary nitrogen atom.
[0287] It should be understood that the compounds of this disclosure, for example, salts of the compounds, may exist in hydrated or unhydrated (anhydrous) forms, or as solvates with other solvent molecules. Non-limiting examples of hydrates include monohydrates and dihydrates. Non-limiting examples of solvates include ethanol solvate and acetone solvate.
[0288] As used herein, the term “solvate” means a solvation form containing a stoichiometric or non-stoichiometric amount of solvent. Some compounds tend to capture solvent molecules in a certain molar ratio in their crystalline solid state and thus form solvates. When the solvent is water, the solvate formed is a hydrate; when the solvent is an alcohol, the solvate formed is an alcoholate. Hydrates are formed by a combination of one or more water molecules and one substance molecule, where the water remains in its molecular state as H2O.
[0289] As used herein, the term “analog” refers to a compound that is structurally similar to another but has a slightly different composition (for example, by replacing one atom with an atom of a different element, or by the presence of a particular functional group, or by replacing one functional group with another). Thus, an analog is a compound that is similar or equivalent to a reference compound in function and appearance, but differs from the reference compound in structure or origin.
[0290] As used herein, the term “derivative” refers to a compound having a common core structure and being substituted with one of the various groups described herein.
[0291] The term "biological equivalent" refers to a compound resulting from the exchange of an atom or group of atoms with another atom or group of atoms that is broadly similar. The purpose of biological equivalent substitution is to create a new compound that has similar biological properties to the parent compound. Biological equivalent substitution may be based on physicochemical or topological considerations. Examples of biological equivalents of carboxylic acids include, but are not limited to, acylsulfonimides, tetrazoles, sulfonates, and phosphonates. See, for example, Patani and LaVoie, Chem. Rev. 96, 3147-3176, 1996.
[0292] It should be understood that this disclosure is intended to include all isotopes of the atoms present in the compounds of the present invention. Isotopes include atoms that have the same atomic number but different mass numbers. As a general example, but not limited to, isotopes of hydrogen include tritium and deuterium, and isotopes of carbon include C-13 and C-14.
[0293] As used herein, expressions such as "one or more of A, B, or C," "one or more A, B, or C," "one or more of A, B, and C," "one or more A, B, and C," "selected from the group consisting of A, B, and C," and "selected from A, B, and C" are used interchangeably and, unless otherwise specified, all refer to a selection from the group consisting of A, B, and / or C, i.e., one or more A, one or more B, one or more C, or any combination thereof.
[0294] It should be understood that this disclosure provides methods for synthesizing any of the compounds of the formulas described herein. This disclosure also provides detailed methods for synthesizing various disclosed compounds according to the schemes shown below and in the examples.
[0295] Throughout this specification, where a composition is described as having, including, or comprise certain components, it should be understood that the composition is also intended to consist essentially of or comprise those components. Similarly, where a method or process is described as having, including, or comprise certain process steps, the process also consists essentially of or comprises those enumerated processing steps. Furthermore, it should be understood that the order of the steps or the order in which certain operations are performed is not important, as long as the invention is operable. Moreover, two or more steps or operations can be performed simultaneously.
[0296] It should be understood that the synthesis process described herein is tolerant of a wide range of functional groups and therefore can use a variety of substituted starting materials. The process generally provides the desired final compound at or near the end of the entire process, but in some cases it may be desirable to further convert the compound to its pharmaceutically acceptable salt.
[0297] It should be understood that the compounds disclosed herein can be prepared in a variety of ways by using commercially available starting materials, compounds known in the literature, or readily prepared intermediates, and by using standard synthetic methods and procedures known to those skilled in the art or evident to those skilled in the art in light of the teachings herein. Standard synthetic methods, as well as procedures for the preparation of organic molecules and the transformation and manipulation of functional groups, can be obtained from relevant scientific literature or standard textbooks in the field. Not limited to any one or more sources, but incorporated herein by reference, is Smith, MB, March, J., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5 th edition,John Wiley & Sons:New York,2001;Greene,TW,Wuts,PGM,Protective Groups in Organic Synthesis,3 rdClassic texts such as John Wiley & Sons, New York, 1999; R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995) are useful and recognized reference texts for organic synthesis known to those skilled in the art.
[0298] Unless otherwise stated, any description of a treatment method should be understood to include the use of compounds to provide treatment or prevention as described herein, and the use of compounds to prepare agents for treating or preventing such conditions. Treatment includes treatment of humans or non-human animals, including rodents and other disease models.
[0299] As used herein, the term “subject” is interchangeable with the term “subject in need of it,” both referring to subjects who have the disease or are at high risk of developing the disease. “Subject” includes mammals. Mammals may be, for example, humans or suitable non-human mammals, such as primates, mice, rats, dogs, cats, cattle, horses, goats, camels, sheep, or pigs. Subjects may also be birds or poultry. In one embodiment, the mammal is a human.
[0300] As used herein, the terms “to treat” or “to heal” describe the management and care of a patient aimed at combating a disease, condition, or disorder, and include administering the compounds of the Disclosure or their pharmaceutically acceptable salts, polymorphs, or solvates to alleviate the symptoms or complications of a disease, condition, or disorder, or to eliminate the disease, condition, or disorder. The terms “to heal” may also include the treatment of in vitro cell or animal models.
[0301] It should be understood that the compounds disclosed herein, or any pharmaceutically acceptable salts, polymorphs, or solvates thereof, may be used, or are permitted to be used, to prevent related diseases, conditions, or disorders, or to identify suitable candidates for such purposes.
[0302] As used herein, the terms “prevent,” “prevent,” or “protect from” mean to reduce or eliminate the onset of symptoms or complications of such disease, condition, or disorder.
[0303] Those skilled in the art will understand that they can refer to general reference texts for a detailed description of the known or equivalent technologies discussed herein. These texts include Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Inc. (2005); Sambrook et al., Molecular Cloning, A Laboratory Manual (3 rdedition),Cold Spring Harbor Press,Cold Spring Harbor,New York(2000);Coligan et al.,Current Protocols in Immunology,John Wiley & Sons,NY;Enna et al.,Current Protocols in Pharmacology,John Wiley & Sons,NY;Fingl et al.,The Pharmacological Basis of Therapeutics(1975),Remington´s Pharmaceutical Sciences,Mack Publishing Co.,Easton,PA,18 th This includes Mandell, et al., Principles and Practice of Infectious Diseases, Saunders Publishing (8th edition, 2014), edition (1990). Of course, these texts can also be referenced when manufacturing or using any aspect of this disclosure.
[0304] As used herein, the terms “combination therapy” or “co-therapy” include the administration of the compounds of this disclosure or their pharmaceutically acceptable salts, polymorphs, or solvates, and at least a second drug, as part of a particular therapeutic regimen intended to provide a beneficial effect through the co-action of these therapeutics. The beneficial effect of the combination includes, but is not limited to, pharmacokinetic or pharmacodynamic synergies resulting from the combination of therapeutics.
[0305] It should be understood that this disclosure also provides pharmaceutical compositions comprising any of the compounds described herein in combination with at least one pharmaceutically acceptable excipient or carrier.
[0306] As used herein, the term “pharmaceutical composition” means a formulation comprising the compound of this disclosure in a form suitable for administration to a subject. In one embodiment, the pharmaceutical composition is a bulk or unit dosage form. The unit dosage form is any of various forms, including, for example, capsules, IV bags, tablets, a single pump or vial of an aerosol inhaler. The amount of the active ingredient (e.g., formulations of the disclosed compound or its salts, hydrates, solvates, or isomers) in a unit dose of the composition is an effective amount and varies according to the specific treatment involved. Those skilled in the art will understand that it may be necessary to change the dosage on a daily basis depending on the patient’s age and condition. The dosage also depends on the route of administration. Various routes are intended, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, inhalation, oral cavity, sublingual, intrathoracic, intrathecal, nasal, etc. Dosage forms for topical or transdermal administration of the compounds of this disclosure include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. In one embodiment, the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any necessary preservatives, buffers, or propellants.
[0307] The terms “effective dose” and “therapeutic dose” of a drug or compound are used most broadly to refer to a non-toxic but sufficient amount of active drug or compound to provide the desired effect or benefit.
[0308] The term “benefit” is used in its broadest sense to refer to any desirable effect, specifically including clinical benefits as defined herein. Clinical benefits can be measured by evaluating various endpoints, such as inhibition of disease progression to a certain extent, including delayed and complete cessation; a reduction in the number of disease events and / or symptoms; a reduction in lesion size; inhibition of the infiltration of disease cells into adjacent peripheral organs and / or tissues (i.e., reduction, delay, or complete cessation); inhibition of disease spread (i.e., reduction, delay, or complete cessation); a reduction in autoimmune responses that may, but not necessarily, result in regression or elimination of disease lesions; a reduction to a certain extent of one or more symptoms associated with the disorder; a period of disease-free life after treatment, such as increased progression-free survival; increased overall survival; a higher response rate; and / or a reduction in mortality at a given time after treatment.
[0309] As used herein, the term “pharmaceutically acceptable” means a compound, anion, cation, material, composition, carrier, and / or dosage form that is within the bounds of sound medical judgment, suitable for use in contact with human and animal tissues, free from excessive toxicity, irritation, allergic reactions, or other problems or complications, and commensurate with a reasonable benefit / risk ratio.
[0310] As used herein, the term “pharmaceutically acceptable excipient” means an excipient that is generally safe, non-toxic, and useful for preparing a pharmaceutical composition that is not biologically or otherwise undesirable, and includes excipients acceptable for veterinary and human medicinal use. As used herein and in the claims, “pharmaceutically acceptable excipient” includes both one and more such excipients.
[0311] It should be understood that the pharmaceutical compositions of this disclosure are formulated to be suitable for their intended route of administration. Examples of routes of administration include parenteral administration, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), and transmucosal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application may contain the following components: sterile diluents, e.g., water for injection, saline, fixative oil, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents; antimicrobial agents, e.g., benzyl alcohol or methylparaben; antioxidants, e.g., ascorbic acid or sodium bisulfite; chelating agents, e.g., ethylenediaminetetraacetic acid; buffers, e.g., acetates, citrates, or phosphates; and tonicity adjusters, e.g., sodium chloride or dextrose. The pH may be adjusted using an acid or base such as hydrochloric acid or sodium hydroxide. Parenteral formulations may be sealed in glass or plastic ampoules, disposable syringes, or multi-dose vials.
[0312] It should be understood that the compounds or pharmaceutical compositions of this disclosure can be administered to subjects by many of the well-known methods currently used for chemotherapy. For example, the compounds of this disclosure may be injected into the bloodstream or body cavities, taken orally, or applied through the skin using a patch. The selected dose must be sufficient to constitute an effective treatment, but should not be so high as to cause unacceptable side effects. The disease state and the patient's health condition should preferably be carefully monitored for a reasonable period during and after treatment.
[0313] As used herein, the term “therapeutic dose” refers to the amount of an agent used to treat, improve, or prevent a specific disease or condition, or to produce a detectable therapeutic or inhibitory effect. The effect can be detected by any assay known in the art. The exact effective dose for a subject depends on the subject’s weight, size, and health status, the nature and severity of the condition, and the therapeutic agent or combination of therapeutic agents selected for administration. A therapeutic dose for a given condition can be determined by routine experimentation within the scope of the clinician’s skill and judgment.
[0314] It should be understood that for any compound, the therapeutically effective dose can first be estimated using either a cell culture assay, such as one involving tumor cells, or an animal model (usually rats, mice, rabbits, dogs, or pigs). Animal models can also be used to determine appropriate concentration ranges and routes of administration. Such information can then be used to determine useful doses and routes of administration for human administration. Therapeutic / prophylactic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose that is therapeutically effective in 50% of the population) and LD50 (the dose that is lethal in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as the LD50 / ED50 ratio. Pharmaceutical compositions exhibiting a large therapeutic index are preferred. Dosages may vary within this range depending on the dosage form used, patient sensitivity, and route of administration.
[0315] Dosage and administration are adjusted to provide a sufficient level of active agent or to maintain the desired effect. Factors to consider include the severity of the disease state, the subject's overall health, age, weight, and sex, diet, timing and frequency of administration, drug combinations, sensitivity to response, and tolerability / response to treatment. Long-acting pharmaceutical compositions may be administered once every 3-4 days, once a week, or once every 2 weeks, depending on the half-life and clearance rate of the particular formulation.
[0316] Pharmaceutical compositions comprising the active compound of this disclosure may be manufactured by commonly known methods, such as conventional mixing, dissolution, granulation, sugar-coated tablet manufacturing, levigating, emulsification, encapsulation, encapsulation, or lyophilization processes. The pharmaceutical compositions may also be formulated conventionally using one or more pharmaceutically acceptable carriers comprising excipients and / or adjuvants that facilitate the processing of the active compound into a pharmaceutically usable formulation. Of course, the appropriate formulation depends on the chosen route of administration.
[0317] Suitable pharmaceutical compositions for injection include sterile aqueous solutions (if water-soluble) or dispersions, and sterile powders for the immediate preparation of sterile injection solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL® (BASF, Parsippany, New Jersey), or phosphate-buffered saline (PBS). In all cases, the composition must be sterile and liquid enough to be easily injected. It must be stable under manufacturing and storage conditions and protected from contamination by microorganisms such as bacteria and fungi. Carriers may be solvents or dispersion media containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. Adequate fluidity can be maintained, for example, by the use of coatings such as lecithin, maintaining the required particle size in the case of dispersions, and by the use of surfactants. Prevention of microbial action can be achieved by various antimicrobial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, and thimerosal. In many cases, it is preferable to include isotonic agents, such as sugars, polyhydric alcohols such as mannitol and sorbitol, and sodium chloride in the composition. Sustained absorption of the injectable composition can be achieved by including absorption-delaying agents, such as aluminum monostearate and gelatin, in the composition.
[0318] Sterile injectable solutions can be prepared by incorporating the required amount of the active compound, along with one or a combination of the components listed above, into a suitable solvent, and then sterilizing by filtration. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle containing a basic dispersion medium and other necessary components from those listed above. In the case of sterile powders for preparing sterile injectable solutions, the preparation methods are vacuum drying and freeze-drying, which yield powders of the active ingredient and any additional desired components from a pre-sterilized filtered solution.
[0319] Oral compositions generally contain an inert diluent or a pharmaceutically acceptable food-grade carrier. These can be encapsulated in gelatin capsules or compressed into tablets. For oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, lozenges, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, where the compound in the fluid carrier is applied orally, swished in the mouth, spat out, or swallowed. Pharmaceutically compatible binders and / or auxiliary materials may be included as part of the composition. Tablets, pills, capsules, lozenges, etc., may contain any of the following ingredients or compounds of similar properties: binders such as microcrystalline cellulose, tragacanth gum, or gelatin; excipients such as starch or lactose; disintegrants such as alginic acid, Primogel, or corn starch; lubricants such as magnesium stearate or sterotes; flow promoters such as colloidal silicon dioxide; sweeteners such as sucrose or saccharin; or flavoring agents such as peppermint, methyl salicylate, or orange flavoring.
[0320] For administration by inhalation, the compound is delivered in the form of an aerosol spray from a pressurized container or dispenser or nebulizer containing a suitable propellant, such as a gas including carbon dioxide.
[0321] Systemic administration can also be performed via mucosal or transdermal means. In mucosal or transdermal administration, a penetrating agent suitable for the barrier to be penetrated is used in the formulation. Such penetrating agents are generally known in the art and, for example, in mucosal administration, include surfactants, bile salts, and fusidic acid derivatives. Mucosal administration can be achieved by the use of nasal sprays or suppositories. In transdermal administration, the active compound is formulated in ointments, gels, or creams, as is generally known in the art.
[0322] The active compound can be prepared with a pharmaceutically acceptable carrier that protects the compound from rapid removal from the body, such as a controlled-release formulation including implants and microencapsulation delivery systems. Biodegradable, biocompatible polymers, such as ethylene vinyl acetate, polyanhydride, polyglycolic acid, collagen, polyorthoesters, and polylactic acid, can be used. Methods for preparing such formulations will be apparent to those skilled in the art. The materials are also commercially available from Alza Corporation and Nova Pharmaceuticals, Inc. Liposome suspensions (containing liposomes that target infected cells and include monoclonal antibodies against viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
[0323] For ease of administration and uniformity of dosage, it is particularly advantageous to formulate oral or parenteral compositions in dosage unit forms. As used herein, a dosage unit form refers to a physically distinct unit suitable as a unit dose for the target being treated, each unit containing a predetermined amount of the active compound calculated to produce the desired therapeutic effect in conjunction with the necessary pharmaceutical carrier. The specifications of the dosage unit forms in this disclosure are determined by and directly depend on the inherent properties of the active compound and the specific therapeutic effect to be achieved.
[0324] In therapeutic applications, the dosage of a pharmaceutical composition used in accordance with this disclosure will vary depending on the drug, the age, weight, and clinical condition of the recipient patient, and the experience and judgment of the clinician or healthcare professional administering the treatment, among other factors that may influence the selected dosage. Generally, the dose needs to be sufficient to delay, preferably regress, and more preferably cause complete regression of the disease symptoms. An effective dose of a drug is the amount that produces an objectively identifiable improvement as noted by a clinician or other qualified observer. Improvement in survival and growth indicates regression. As used herein, the term “dosage effective” refers to the amount of the active compound necessary to produce the desired biological effect in a subject or cell.
[0325] Please understand that pharmaceutical compositions may be included in containers, packaging, or dispensers along with instructions for administration.
[0326] Furthermore, in the case of compounds of this disclosure that can form salts, it should be understood that all of these forms are also intended to be within the scope of the claims.
[0327] As used herein, the term “pharmaceutically acceptable salt” refers to a derivative of a compound of the disclosed which is modified by the parent compound to produce an acid or base salt thereof. In some embodiments, a pharmaceutically acceptable salt of a compound (e.g., a β-lactam compound or probenecid as described herein) is also a prodrug of that compound. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of basic residues such as amines, and alkali or organic salts of acidic residues such as carboxylic acids. pharmaceutically acceptable salts include, for example, conventional non-toxic salts or quaternary ammonium salts of the parent compound formed from non-toxic inorganic or organic acids. For example, such commonly used non-toxic salts include 2-acetoxybenzoic acid, 2-hydroxyethanesulfonic acid, acetic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, bicarbonate, carbonic acid, citric acid, edetic acid, ethanedisulfonic acid, 1,2-ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, glycolyarsanilic acid, hexylresorcinol, and hydrabamic acid. This includes, but is not limited to, inorganic and organic acids selected from (acid), hydrobromic acid, hydrochloric acid, hydroiodic acid, hydroxymaleic acid, hydroxynaphthoic acid, isethionic acid, lactic acid, lactobionic acid, laurylsulfonic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, napsylic acid, nitric acid, oxalic acid, pamoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, polygalacturonic acid, propionic acid, salicylic acid, stearic acid, subacetic acid, succinic acid, sulfamic acid, sulfanilic acid, sulfuric acid, tannic acid, tartaric acid, and toluenesulfonic acid, as well as those derived from commonly present amino acids, such as glycine, alanine, phenylalanine, and arginine.
[0328] As used herein, the term “metabolites” means metabolites of the compounds disclosed or their pharmaceutically acceptable salts, solvates, diastereomers, and polymorphs that exhibit similar activity in vivo to the compounds disclosed or their pharmaceutically acceptable salts, solvates, diastereomers, and polymorphs.
[0329] Other examples of pharmaceutically acceptable salts include hexanoic acid, cyclopentanepropionic acid, pyruvate, malonic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo-[2.2.2]-octo-2-ene-1-carboxylic acid, 3-phenylpropionic acid, trimethylacetic acid, quaternary butylacetic acid, muconic acid, etc. The disclosure also includes salts formed when an acidic proton present in the parent compound is substituted with a metal ion, such as an alkali metal ion, an alkaline earth ion, or an aluminum ion, or when it coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, or N-methylglucamine. In salt form, it should be understood that the ratio of the compound to the salt's cation or anion can be 1:1, or any other ratio, such as 3:1, 2:1, 1:2, or 1:3.
[0330] It should be understood that all references to pharmaceutically acceptable salts include the solubilated form (solvate) or crystalline form (polymorph) of the same salt as defined herein.
[0331] As used herein, the term “prodrug” refers to any agent that, when administered to a mammal, is converted in whole or in part to a targeted compound (e.g., any of the fumagirol derivatives described herein). In some embodiments, the prodrug of a compound (e.g., any of the fumagirol derivatives described herein) is also a pharmaceutically acceptable salt of the compound.
[0332] It should be understood that the compounds of this disclosure can also be prepared as esters, for example, pharmaceutically acceptable esters. For example, carboxylic acid functional groups in the compounds can be converted to their corresponding esters, such as methyl, ethyl, or other esters. Alcohol groups in the compounds can also be converted to their corresponding esters, such as acetate, propionic acid, or other esters.
[0333] The compound or a pharmaceutically acceptable salt thereof may be administered orally, nasally, dermatologically, pulmonaryly, by inhalation, orally, sublingually, intraperitoneally, subcutaneously, intramuscularly, intravenously, rectally, intrathoracically, intrathecally, and parenterally. In one embodiment, the compound is administered orally. Those skilled in the art will recognize the advantages of specific routes of administration.
[0334] The dosage regimen utilizing the compound is selected according to various factors, including the patient's type, breed, age, weight, body surface area (BSA), sex, and condition, the severity of the condition being treated, the route of administration, the patient's renal and hepatic function, and the specific compound or salt thereof used. A typical, experienced physician or veterinarian can easily determine and prescribe the effective dose of the drug necessary to prevent, hinder, or halt the progression of the condition.
[0335] The formulations and administration techniques for the compounds disclosed in this disclosure are described in Remington: The Science and Practice of Pharmacy, 19 th This can be found in edition, Mack Publishing Co., Easton, PA (1995). In one embodiment, the compounds described herein and their pharmaceutically acceptable salts are used in combination with a pharmaceutically acceptable carrier or diluent in a pharmaceutical formulation. Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions. The compounds will be present in such a pharmaceutical composition in an amount sufficient to provide a desired dose within the range described herein.
[0336] Other features and advantages of this disclosure will become apparent from the different embodiments. The provided embodiments illustrate components and methodologies that are useful in carrying out this disclosure. The embodiments do not limit the disclosures set forth in the claims. Based on this disclosure, those skilled in the art can identify and use other components and methodologies that are useful in carrying out this disclosure.
[0337] In the synthetic schemes described herein, compounds may be depicted in one particular configuration for simplification. Such particular configurations should not be construed as limiting this disclosure to one or another isomer, tautomer, regioisomer, or stereoisomer, nor should they exclude mixtures of isomers, tautomers, regioisomers, or stereoisomers. However, it will be understood that a given isomer, tautomer, regioisomer, or stereoisomer may have a higher level of activity than another isomer, tautomer, regioisomer, or stereoisomer.
[0338] Compounds designed, selected, and / or optimized by the methods described above can, once generated, be characterized using a variety of assays known to those skilled in the art to determine whether the compounds possess biological activity. For example, molecules can be characterized by conventional assays, including but not limited to those described herein, to determine whether they possess predicted or unexpected activity, target-binding activity, and / or binding specificity.
[0339] Furthermore, high-throughput screening can be used to accelerate analysis using such assays. As a result, it may be possible to rapidly screen the molecules described herein for activity using techniques known in the art. General methodologies for performing high-throughput screening are described, for example, in Devlin (1998) High Throughput Screening, Marcel Dekker and U.S. Patent No. 5,763,263. One or more different assay techniques may be used in high-throughput assays, including but not limited to those described below. [Examples]
[0340] Example 1
[0341] The following are non-limiting examples demonstrating that the MetAP2 inhibitor and CDK4 / 6 inhibitor of this disclosure can be used in combination to treat cancer. Furthermore, the following non-limiting examples demonstrate that the combination of the MetAP2 inhibitor and CDK4 / 6 inhibitor of this disclosure exhibits unexpectedly superior antitumor activity compared to the use of either agent alone.
[0342] In the following experiments, mice with MCF-7 tumors were treated with either a vehicle control, compound 1 alone, palbociclib alone, or a combination of compound 1 and palbociclib. Three days before cell inoculation, female nude mice (Charles River) were first transplanted with one 90-day (0.72 mg) β-estradiol pellet. MCF-7 cells (5 × 10⁶ in 1:1 PBS / Matrigel) were then inoculated. 6 The drug was injected into the fourth mammary gland of mice. The average tumor volume in the group was 125-175 mm². 3 The tumor was 100 mm 3When the tumor size fell below a certain level, administration of various therapeutic drugs was initiated. Throughout the experiment, tumor volume and body weight were measured twice a week, and overall observations were performed daily. At the end of the study, whole blood was collected from treated mice by cardiac puncture for complete blood cell counting (CBC). Furthermore, the tumors of the mice were dissected and analyzed.
[0343] The experimental design is summarized in Table 2. [Table 2]
[0344] The mice in Group 1 (Group No. 1) were administered the vehicle control once daily (QD) via forced oral administration, starting on day 2 of the study and continuing until the end of the experiment.
[0345] The mice in Group 2 (Group No. 2) were administered compound 1 at a dose of 8 mg / kg every four days by subcutaneous injection (Q4D) starting on day 1 of the study and continuing until the end of the study.
[0346] Group 3 mice (group number 3) received compound 1 at a dose of 8 mg / kg every four days by subcutaneous injection, starting on day 1 of the study and continuing until the end of the study. They also received palbociclib at a dose of 20 mg / kg once daily (QD) by forced oral administration, starting on day 2 of the study and continuing until the end of the study.
[0347] Group 4 mice (group number 4) received compound 1 at a dose of 8 mg / kg every four days by subcutaneous injection, starting on day 1 of the study and continuing until the end of the study. They also received palbociclib at a dose of 40 mg / kg once daily (QD) by forced oral administration, starting on day 2 of the study and continuing until the end of the study.
[0348] Group 5 mice (group number 5) were administered palbociclib at a dose of 20 mg / kg once daily (QD) by forced oral administration, starting on day 2 of the study and continuing until the end of the study.
[0349] Group 6 mice (group number 6) were administered palbociclib at a dose of 40 mg / kg once daily (QD) by forced oral administration, starting on day 2 of the study and continuing until the end of the study.
[0350] Compound 1 was dissolved in a 5% mannitol aqueous solution (w / v), filtered for sterilization, and then administered to mice by subcutaneous injection.
[0351] Palbociclib was dissolved in lactate buffer (50 mM, pH 4.0), filtered sterile, and then administered to mice by forced oral administration.
[0352] Figure 1 shows an analysis of MCF tumor volume throughout the study. Figure 2 shows the MCF tumor volume at the end of the study (day 31). As shown in Figures 1 and 2, the combination of compound 1 and palbociclib resulted in a greater reduction in tumor volume compared to compound 1 alone or palbociclib alone.
[0353] Figure 3 shows the changes in body weight in various experimental groups.
[0354] Figure 4 shows the survival rates of each experimental group throughout the research process.
[0355] As those skilled in the art will understand, several genes and cellular pathways are involved in the acquisition of resistance to CDK4 / 6 inhibitors such as palbociclib and ribociclib, including but not limited to cyclin E1, CDK2, CDK4, Akt signaling, autophagy pathways, and cancer stem cell initiation pathways. To that end, to determine how the combined administration of the MetAP2 inhibitor and CDK4 / 6 inhibitor of this disclosure may affect the expression of various proteins involved in CDK4 / 6 inhibitor resistance, the expression levels of various proteins were analyzed in tumor samples collected at the end of the study.
[0356] Figure 5 shows the expression levels of cyclin D1 protein in tumor samples collected at the end of the study in each experimental group.
[0357] Figure 6 shows the expression levels of cyclin E1 protein in tumor samples collected at the end of the study in each experimental group. As will be understood by those skilled in the art, cyclin E1 expression levels in metastatic breast cancer are associated with the response to palbociclib. Specifically, in a clinical trial of women with ER+ / Her2- metastatic breast cancer, palbociclib and fulvestrant were significantly less effective (shorter progression-free survival) when tumors expressed high levels of cyclin E1 compared to tumors with low cyclin E1 expression (Turner, DOI:10.1200 / JCO.18.00925 Journal of Clinical Oncology 37, no. 14 (May 10, 2019) 1169-1178).
[0358] Figure 7 shows the expression levels of cyclin E2 protein in tumor samples collected at the end of the study in each experimental group. As shown in Figure 7, treatment with the combination of compound 1 and palbociclib resulted in a decrease in cyclin E2 protein levels in tumor samples compared to both the vehicle control, compound 1 alone, or palbociclib alone. As will be understood by those skilled in the art, cyclin E2 expression levels are associated with tumor progression in ER+ breast cancer, and patients with high cyclin E2 expression have been observed to have shorter overall survival or recurrence-free survival (Sieuwerts, 2006, Clinical Cancer Research 12 3319-3328 (https: / / doi.org / 10.1158 / 1078-0432.CCR-06-0225; Millioli, Endocrine-Related Cancer (2020) 27, R93-R112)).
[0359] Figure 8 shows the expression levels of the p21 protein in tumor samples collected at the end of the study in each experimental group.
[0360] Figure 9 shows the expression levels of CDK4 protein in tumor samples collected at the end of the study in each experimental group. As shown in Figure 9, treatment with the combination of compound 1 and palbociclib resulted in a decrease in CDK4 protein levels in tumor samples compared to both vehicle control, compound 1 alone, or palbociclib alone.
[0361] Figure 10 shows the expression levels of the CDK2 protein in tumor samples collected at the end of the study in each experimental group. As shown in Figure 10, treatment with the combination of compound 1 and palbociclib resulted in a decrease in CDK2 protein levels in tumor samples compared to both vehicle control, compound 1 alone, or palbociclib alone.
[0362] Figure 11 shows the Rb protein expression levels in tumor samples collected at the end of the study in each experimental group. As shown in Figure 11, treatment with the combination of compound 1 and palbociclib resulted in a decrease in Rb protein levels in tumor samples compared to both the vehicle control, compound 1 alone, or palbociclib alone. As will be understood by those skilled in the art, the level of Rb protein expression in metastatic breast cancer is associated with the response to palbociclib. Specifically, in a clinical trial of women with ER+ / Her2- metastatic breast cancer, palbociclib and fulvestrant were significantly less effective (shorter progression-free survival) when tumors expressed high levels of Rb protein compared to tumors with low Rb protein expression (Turner, DOI:10.1200 / JCO.18.00925 Journal of Clinical Oncology 37, no. 14 (May 10, 2019) 1169-1178).
[0363] Figure 12 shows the changes in the autophagy protein LC3B measured in tumor tissue at the end of the study. As will be understood by those skilled in the art, LC3B is a marker of autophagy. As will be understood by those skilled in the art, CDK4 / 6 inhibitors can induce autophagy (Vijayaraghavan, S. et al. CDK4 / 6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers: Nat.Commun. 8, 15916 doi:10.1038 / ncomms15916 (2017)). As shown in Figure 12, the combination of palbociclib and compound 1 reduces the induction of the LC3B autophagy protein.
[0364] Figure 13 shows the expression levels of Akt protein in tumor samples collected at the end of the study in each experimental group. As shown in Figure 13, treatment with the combination of compound 1 and palbociclib resulted in a decrease in Akt protein levels in tumor samples compared to both vehicle control, compound 1 alone, or palbociclib alone.
[0365] Figure 14 shows the expression levels of phospho-Akt protein in tumor samples collected at the end of the study in each experimental group. As shown in Figure 14, treatment with compound 1 alone and compound 1 in combination with high doses of palbociclib resulted in a decrease in phospho-Akt protein levels compared to compound 1 in combination with low doses of palbociclib and palbociclib alone.
[0366] Figure 15 shows the expression levels of estrogen receptor alpha (ERα)-62kDa protein in tumor samples collected at the end of the study in each experimental group. As shown in Figure 15, treatment with compound 1 and palbociclib combination resulted in a decrease in ERα-62kDa protein levels.
[0367] Figure 16 shows the expression levels of ERα-55kDa protein in tumor samples collected at the end of the study in each experimental group. As shown in Figure 16, treatment with the combination of compound 1 and 20 mg / kg palbociclib resulted in a greater decrease in ERα-55kDa protein levels than treatment with 20 mg / kg palbociclib alone.
[0368] Figure 17 shows the total expression levels of ERα-55kDa and ERα-62kDa proteins in tumor samples collected at the end of the study in each experimental group.
[0369] Figure 18 shows the expression levels of PHGDH protein in tumor samples collected at the end of the study in each experimental group. As shown in Figure 18, treatment with the combination of compound 1 and palbociclib resulted in a greater decrease in PHGDH protein levels than treatment with compound 1 alone or palbociclib alone.
[0370] Figure 19 shows the number of neutrophils in whole blood collected at the end of the study in each experimental group. As shown in Figure 19, both palbociclib and SDX-7320 alone suppressed neutrophil levels by 30–40% compared to vehicle-treated mice, but the combination of SDX-7320 and palbociclib (40 mg / kg) increased neutrophils by 49% compared to vehicle-treated mice. As those skilled in the art will understand, neutropenia is the main side effect of palbociclib. Therefore, although we do not wish to be bound by theory, these results indicate that the combination of compound 1 and palbociclib mitigates palbociclib-induced neutropenia, thereby improving the hematological safety profile.
[0371] The results shown in this embodiment demonstrate that the combination of the MetAP2 inhibitor and CDK4 / 6 inhibitor of this disclosure, more specifically palbociclib, can be used to treat cancer and prevent CDK4 / 6 treatment resistance. Furthermore, the results shown in this embodiment demonstrate that the combination of the MetAP2 inhibitor and CDK4 / 6 inhibitor of this disclosure induces changes in gene expression consistent with increased patient survival and reduced levels of CDK4 / 6 inhibitor resistance. While we do not wish to be bound by theory, these changes in gene expression suggest that the combination of the MetAP2 inhibitor and CDK4 / 6 inhibitor of this disclosure can overcome existing limitations of CDK4 / 6 inhibitor therapy.
[0372] Example 2
[0373] The following are non-limiting examples demonstrating that cancer can be treated using a combination of the MetAP2 inhibitor and CDK4 / 6 inhibitor of this disclosure. Furthermore, the following non-limiting examples demonstrate that the combination of the MetAP2 inhibitor and CDK4 / 6 inhibitor of this disclosure exhibits unexpectedly superior antitumor activity compared to the use of either agent alone. As will be understood by those skilled in the art, several genes and cellular pathways are involved in the acquisition of resistance to CDK4 / 6 inhibitors such as palbociclib and ribociclib, including but not limited to cyclin E1, CDK2, CDK4, Akt signaling, autophagy pathways, and cancer stem cell initiation pathways. For this purpose, the expression levels of various proteins were analyzed in tumor samples collected at the end of the study to determine how the combination administration of the MetAP2 inhibitor and CDK4 / 6 inhibitor of this disclosure may affect the expression of various proteins involved in CDK4 / 6 inhibitor resistance.
[0374] Tumor samples from mice treated in Example 1 were subjected to further analysis. Briefly, tumors isolated from mice were placed in RNALater solution and then frozen at -70°C. PolyA+ RNA was then isolated and reverse transcribed into cDNA. The cDNA was then analyzed by sequencing. The sequenced data was aligned to the human genome (GRCh38) to provide relative RNA expression levels for each gene mentioned in each animal and in GRCh38. Statistical analysis was then performed to identify genes and pathways that were specifically regulated when mice were treated with the combination of compound 1 and palbociclib, in contrast to when mice were treated with monotherapy.
[0375] As will be understood by those skilled in the art, gene set enrichment analysis (GSEA) was performed using standard methods in the art. Specifically, the gene set KEGG_ONE_CARBON_POOL_BY_FOLATE was analyzed in tumors from mice treated with a combination of 8 mg / kg of compound 1 (SC) and 40 mg / kg of palbociclib (PO), and from mice treated with 40 mg / kg of palbociclib alone (PO). GSEA analysis demonstrated that the genes MTHFD1L, TYMS, ALDH1L1, MTHFD1, MTHFD2, GART, SHMT1, DHFR, MTR, SHMT2, and MTFMT were expressed less in tumors from mice treated with the combination of compound 1 and palbociclib compared to tumors from mice treated with palbociclib alone. As will be understood by those skilled in the art, the aforementioned genes are biologically related to metabolism.
[0376] Based on the analysis described above, the expression levels of the genes PHGDH, PSPH, TYMS, MTHFD1L, MTHFD1, MTHFD2, SHMT1, SHMT2, and DHFR were analyzed in tumor samples isolated from each treatment group shown in Example 1.
[0377] Figure 20 shows the expression levels of PHGDH (phosphoglycerate dehydrogenase) in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 20, treatment with the combination of compound 1 and palbociclib resulted in a greater reduction in PHGDH levels compared to treatment with compound 1 alone or palbociclib alone. As will be understood by those skilled in the art, a reduction in PHGDH reduces the de novo synthesis of serine and glycine, which cancer cells have been shown to depend on for multiple cellular processes (see Zhao X, Fu J, Du J, Xu W. Int J Biol Sci. 2020;16(9):1495-1506). Furthermore, as shown in Figure 30, subjects with high levels of PHGDH expression have an increased risk of recurrence in ER+ breast cancer. Therefore, while we do not wish to be bound by theory, the reduction in PHGDH expression induced by treatment with compound 1 and a CDK4 / 6 inhibitor combination may help reduce the risk of recurrence and extend survival in subjects with cancer, including ER+ breast cancer.
[0378] Figure 21 shows the expression levels of PSPH (phosphoserine phosphatase) in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 21, treatment with the combination of compound 1 and palbociclib resulted in a greater reduction in PSPH levels compared to treatment with compound 1 alone or palbociclib alone.
[0379] Figure 22 shows the expression levels of TYMS (thymidylate synthetase) in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 22, treatment with the combination of compound 1 and palbociclib resulted in a greater reduction in TYMS levels compared to treatment with compound 1 alone or palbociclib alone. As those skilled in the art will understand, a decrease in TYMS1 expression delays the production of pyrimidine nucleotides, which are essential for DNA synthesis and cell proliferation, particularly in the context of cancer cells. Furthermore, as shown in Figure 31, subjects with high levels of TYMS expression have an increased risk of recurrence in ER+ breast cancer. Therefore, although we do not wish to be bound by theory, the reduction in TYMS expression induced by treatment with the combination of compound 1 and a CDK4 / 6 inhibitor may help reduce the risk of recurrence and extend survival in subjects with cancer, including ER+ breast cancer.
[0380] Figure 23 shows the expression levels of MTHFD1L (methylenetetrahydrofolate dehydrogenase-like 1) in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 23, treatment with compound 1 and high-dose palbociclib resulted in a greater decrease in MTHFD1L levels compared to treatment with high-dose or low-dose palbociclib alone. Treatment with compound 1 alone resulted in an increase in MTHFD1L expression.
[0381] Figure 24 shows the expression levels of MTHFD1 (methylenetetrahydrofolate dehydrogenase) in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 24, treatment with compound 1 and high-dose palbociclib resulted in a greater reduction in MTHFD1 levels compared to treatment with compound 1 alone or palbociclib alone.
[0382] Figure 25 shows the expression levels of MTHFD2 (methylenetetrahydrofolate dehydrogenase (NADP+-dependent) 2) in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 25, treatment with compound 1 and high-dose palbociclib resulted in a greater reduction in MTHFD2 levels compared to treatment with high-dose palbociclib alone. Treatment with compound 1 alone and lower-dose palbociclib resulted in an increase in MTHFD2 expression.
[0383] Figure 26 shows the expression levels of SHMT1 (serine hydroxymethyltransferase 1) in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 26, treatment with compound 1 and palbociclib combined resulted in a greater reduction in SHMT1 levels compared to treatment with palbociclib alone.
[0384] Figure 27 shows the expression levels of SHMT2 (serine hydroxymethyltransferase 2) in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 27, treatment with compound 1 and high-dose palbociclib resulted in a greater decrease in SHMT2 levels compared to treatment with palbociclib alone. Treatment with compound 1 alone resulted in an increase in SHMT2 expression.
[0385] Figure 33 shows the expression levels of DHFR (dihydrofolate reductase) in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 33, treatment with the combination of compound 1 and high-dose palbociclib resulted in a greater reduction in DHFR levels compared to treatment with high-dose palbociclib alone and compound 1 alone.
[0386] Furthermore, sequencing analysis of tumor samples showed that tumors in mice treated with compound 1 and palbociclib showed downregulation of the enzymes 3-phosphoglycerate dehydrogenase (PHGDH) and thymidylate synthase (TYMS) compared to tumors in mice treated with compound 1 alone. Without being bound by theory, and as those skilled in the art will understand, the reduction in PHGDH reduces the de novo synthesis of serine and glycine, on which cancer cells are known to depend for multiple cellular processes, and the reduction in enzyme TS expression delays the production of purine nucleotides essential for DNA synthesis and cell proliferation.
[0387] In tumor samples isolated from each experimental group shown in Example 1, the expression levels of genes in the PI3K pathway were also analyzed.
[0388] Figure 28 shows the expression levels of PIK3IP1 in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 28, treatment with compound 1 and high-dose palbociclib resulted in a dramatic increase in PIK3IP1 expression compared to treatment with compound 1 alone or palbociclib alone. As those skilled in the art will understand, PIK3IP1 is an endogenous PI3K inhibitor and tumorigenetic inhibitor (see He X, Zhu Z, Johnson C, et al. Cancer Res. 2008;68(14):5591-5598). Therefore, treatment with compound 1 and palbociclib unexpectedly results in an increase in the expression of the tumor suppressor. As shown in Figure 32, subjects with low levels of PIK3IP1 expression have an increased risk of recurrence in ER+ breast cancer. Therefore, while we do not wish to be bound by theory, the increased PIK3IP1 expression induced by treatment with compound 1 and a CDK4 / 6 inhibitor combination may help reduce the risk of recurrence and extend survival in subjects with ER+ breast cancer.
[0389] Figure 29 shows the expression levels of Greb1 in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 29, treatment with compound 1 and high-dose palbociclib resulted in a greater decrease in Greb1 levels compared to treatment with palbociclib alone. Treatment with compound 1 alone resulted in an increase in Greb1 expression. As will be understood by those skilled in the art, Greb1 is known to be an estrogen-regulated growth promoter in breast cancer and has been shown to be a PI3K activator in vitro (see Haines et al, Carcinogenesis, 2020, Vol. 41, No. 12, 1660-1670). Therefore, treatment with compound 1 and palbociclib unexpectedly results in a reduction in tumor promoter expression.
[0390] In addition to the genes mentioned above, genes from the OnctoType21 gene panel (see Paik, 2004, NEJM, 351(27):2817-26) were also analyzed for breast cancer recurrence. These genes include MybL2, Ki-67, BIRC5 / survivin, CCNB1 / cyclin B1, and SCUBE2.
[0391] Figure 34 shows the expression levels of MybL2 (MYB proto-oncogene 2) in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 34, treatment with compound 1 and high-dose palbociclib resulted in a greater reduction in MybL2 levels compared to treatment with palbociclib alone.
[0392] Figure 35 shows the expression levels of BIRC5 / survivin (containing baculovirus IAP repeat 5) in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 35, treatment with compound 1 and high-dose palbociclib resulted in a greater reduction in BIRC5 / survivin levels compared to treatment with palbociclib alone and compound 1 alone.
[0393] Figure 36 shows the Ki-67 expression levels in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 36, treatment with compound 1 and high-dose palbociclib resulted in a greater reduction in Ki-67 levels compared to treatment with palbociclib alone and compound 1 alone.
[0394] Figure 37 shows the expression levels of CCNB1 / cyclin B1 in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 37, treatment with compound 1 and high dose palbociclib resulted in a greater reduction in CCNB1 / cyclin B1 levels compared to treatment with palbociclib alone and compound 1 alone.
[0395] Figure 38 shows the expression levels of SCUBE2 in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 38, treatment with compound 1 and high dose palbociclib combined resulted in a greater increase in SCUBE2 levels compared to treatment with palbociclib alone and compound 1 alone. As will be understood by those skilled in the art, SCUBE2 is a tumor suppressor that acts in breast cancer through the coordinated suppression of BMP and β-catenin signaling pathways (see Cheng, Cancer Res April 15 2009(69)(8)3634-3641).
[0396] In addition to the genes mentioned above, we analyzed several other genes that regulate cell proliferation, cell metabolism, cell translocation, and / or cell viability.
[0397] Figure 39 shows the expression levels of RRM2, a subunit of ribonucleotide reductase (RNR), in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 39, treatment with compound 1 and palbociclib combined resulted in a greater reduction in RRM2 levels compared to treatment with palbociclib alone and compound 1 alone. As will be understood by those skilled in the art, several chemotherapeutic agents inhibit the activity of RNR, establishing this as a drug target in cancer treatment.
[0398] Figure 40 shows the expression levels of PCLAF (PCNA-related factor) in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 40, treatment with compound 1 and high-dose palbociclib resulted in a greater reduction in PCLAF levels compared to treatment with palbociclib alone and compound 1 alone. As will be understood by those skilled in the art, PCLAF expression is elevated in breast cancer and is associated with cancer stem cell (CSC) characteristics (CSCs are associated with early disease recurrence) and worsening patient outcomes (Wang, Nat Commun. 2016;7:10633).
[0399] Figure 41 shows the expression levels of SLC7A5 / LAT1 in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 41, treatment with compound 1 and high-dose palbociclib resulted in a greater decrease in SLC7A5 / LAT1 levels compared to treatment with palbociclib alone. Furthermore, treatment with compound 1 alone resulted in an increase in SLC7A5 / LAT1 expression. As will be understood by those skilled in the art, SLC7A5 / LAT1 is an amino acid transporter that is upregulated in ER+ breast cancer. Higher expression is associated with the development of resistance to endocrine therapy and a significantly higher risk of breast cancer recurrence (see Mihaly, Breast Cancer Res Treat. 2013;140:219-232 and El Ansari et al. Breast Cancer Research (2018) 20(1):21).
[0400] Figure 42 shows the expression levels of SLC3A2 in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 42, treatment with compound 1 and high dose palbociclib resulted in a greater decrease in SLC3A2 levels compared to treatment with palbociclib alone. Furthermore, treatment with compound 1 alone resulted in an increase in SLC3A2 expression. As will be understood by those skilled in the art, SLC3A2 binds to SLC7A5 to form a functional amino acid transporter complex.
[0401] Figure 43 shows the expression levels of EVL (Ena-VASP-like) in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 43, treatment with compound 1 and palbociclib combined resulted in a greater increase in EVL levels compared to treatment with palbociclib alone. As will be understood by those skilled in the art, EVL is an actin-binding protein that modulates the cytoskeleton of cells. Together with profilin-2, EVL suppresses the metastatic behavior of breast cancer, and patients with the lowest EVL expression have a significantly higher risk of poor outcomes (see Padilla-Rodriguez, Nat Commun. 2018;9(1):2980 and Mouneimne, Cancer Cell. 2012;22(5):615-630).
[0402] Figure 44 shows the expression levels of ANP32E (acid leucine-rich nuclear phosphoprotein 32) in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 44, treatment with compound 1 and high-dose palbociclib resulted in a greater reduction in ANP32E levels compared to treatment with palbociclib alone and compound 1 alone. As will be understood by those skilled in the art, ANP32E is a specific histone chaperone for the mutant histone protein H2AZ1, which removes H2AZ1 from DNA. Elevated ANP32E expression in breast cancer is associated with metastasis and worse outcomes compared to tumors with low expression (see Obri, Nature, 2014, 505:648-653; Xiong, Molecular Oncology, 2018, 12:896-912).
[0403] Figure 45 shows the expression levels of H2AZ1 in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 45, treatment with compound 1 and high-dose palbociclib resulted in a greater reduction in ANP32E levels compared to treatment with palbociclib alone and compound 1 alone. As will be understood by those skilled in the art, H2AZ1 promotes cell proliferation by regulating the transcription of cell cycle proteins and also modulates epithelial-mesenchymal transition (EMT), a cellular mechanism that initiates metastasis. H2AZ1 expression is upregulated in many cancers, including breast cancer, and elevated expression is associated with poor outcomes in breast cancer (Quenet D., Int Rev Cell Mol Biol. 2018;335:1-39). (See reference).
[0404] Figure 46 shows the H2AX expression levels in tumor samples collected at the end of the study in each experimental group shown in Example 1. As shown in Figure 46, treatment with compound 1 and high-dose palbociclib resulted in a greater reduction in H2AX levels compared to treatment with palbociclib alone and compound 1 alone. As will be understood by those skilled in the art, H2AX is known for its role in the DNA damage response and in the formation of the mitotic spindle, which regulates the progression of mitosis during cell division. Lower H2AX levels result in chromosomal abnormalities, increased sensitivity to radiation, and impaired response to DNA double-strand breaks (DSBs) (see Ferrand, Cells, 2020;9(11):2424).
[0405] The results presented in this embodiment demonstrate that the combination of a MetAP2 inhibitor and a CDK4 / 6 inhibitor can be used to treat cancer, as treatment with this combination results in changes in gene expression associated with tumor reduction, decreased metastasis, and increased patient survival. While we do not wish to be bound by theory, these changes in gene expression demonstrate that the combination of the MetAP2 inhibitor and CDK4 / 6 inhibitor presented in this disclosure can overcome the existing limitations of CDK4 / 6 inhibitor therapy. More specifically, the results above show that the combination of compound 1 and the CDK4 / 6 inhibitor results in an unexpectedly large reduction in the expression of genes dependent on tumor cell survival and metastasis, which is not observed with treatment with either compound alone. As will be understood by those skilled in the art, this effect on gene expression may contribute to increased tumor reduction when both compound 1 and the CDK4 / 6 inhibitor are administered.
[0406] Example 3
[0407] The following are non-limiting examples demonstrating that cancer can be treated using a combination of the MetAP2 inhibitor and CDK4 / 6 inhibitor of this disclosure. Furthermore, the following non-limiting examples demonstrate that the combination of the MetAP2 inhibitor and CDK4 / 6 inhibitor of this disclosure exhibits unexpectedly superior antitumor activity compared to the use of the MetAP2 inhibitor alone.
[0408] In the following experiments, mice with MCF-7 tumors were treated with either a vehicle control, compound 1 alone, ribociclib alone, or a combination of compound 1 and ribociclib.
[0409] MCF-7 cells were cultured in DMEM supplemented with 10% FBS. On the day of transplantation, the cells were washed once with phosphate-buffered saline (PBS). After washing, the cells were pelleted (at 1000 rpm for 5 minutes at room temperature) and then counted using a hemocytometer. 5 × 10⁶ cells per mouse. 6 The individual cell concentrations were resuspended in appropriate amounts of PBS and 1:1 Matrigel. The suspensions were kept on ice until transplantation. 48 hours prior to cell transplantation, 17-β-estradiol pellets (0.36 mg, 60-day sustained-release pellet) were subcutaneously implanted between the scapulae of each female Nu / j mouse.
[0410] Mice were anesthetized in an induction chamber with a combination of 4% isoflurane and 2.5 L / min of oxygen. After anesthesia, the mice were positioned ventrally upward and anesthesia was maintained through a suitable nose cone. MCF-7 cell suspension was administered at a rate of 5 × 10⁶ per mouse. 6 The solution was injected into the mammary fat pad in a volume of 100 μl containing individual cells.
[0411] Starting 5 days after cell transplantation, the tumor was measured twice a week (length x width) using a wireless digital caliper in combination with UWAVE-R, and the measurements were recorded. The average tumor volume was approximately 50 mm². 3 Once the tumor size reached ((length × width 2)π / 6), the animals were randomized according to their mean tumor volume and divided into six treatment groups of 10 mice each.
[0412] Day 1 of treatment was designated as "Day 1". As shown in the experimental design summarized in Table 3, mice were administered subcutaneously (SC), orally (PO), or both. The dosage was calculated based on the individual mouse's body weight. [Table 3]
[0413] The mice in Group 1 (Group No. 1) were administered the vehicle control orally once daily (QD).
[0414] The mice in Group 2 (Group No. 2) were administered compound 1 at a dose of 8 mg / kg every four days by subcutaneous injection (Q4D).
[0415] Group 3 mice (group number 3) were administered compound 1 at a dose of 8 mg / kg by subcutaneous injection every 4 days, and ribociclib at a dose of 35 mg / kg by oral administration once daily (QD).
[0416] Group 4 mice (group number 4) were administered compound 1 at a dose of 8 mg / kg by subcutaneous injection every 4 days, and ribociclib at a dose of 70 mg / kg by oral administration once daily (QD).
[0417] Group 5 mice (group number 5) were administered ribociclib at a dose of 35 mg / kg orally once daily (QD).
[0418] Group 6 mice (group number 6) were administered ribociclib at a dose of 70 mg / kg orally once daily (QD).
[0419] Throughout the study, body weight and tumor measurements were recorded twice a week. Administration and measurement were performed when the tumor was 1000 mm. 3The procedure was carried out until the maximum volume was reached or adverse health events (e.g., weight loss exceeding 20%, extreme lethargy, tumor necrosis, etc.) were observed, at which point the mice were euthanized. During euthanasia, the maximum volume of terminal blood sample was obtained by cardiac puncture. 200 μL was separated into a K2EDTA MiniCollect tube for plasma separation, and 420 μL was separated into a MiniCollect serum separation tube for clinical chemistry analysis of half of the mice. For the other half of the mice, more than 200 μL of blood was collected into a K2EDTA MiniCollect tube (LTT) for CBC analysis. Both the plasma and serum MiniCollect blood tubes were centrifuged at 8000 rpm for 5 minutes. Plasma was stored at -80°C for biomarker analysis, and serum and whole blood (LTT) were further analyzed. In addition, tumors from the mice were dissected, weighed, and divided into two parts. Half of the tumor was placed in buffered formalin and stored at room temperature. Half of the tumor was rapidly frozen in liquid nitrogen and stored at -80°C. Adipose tissue (abdomen, pelvis, retroperitoneum, and inguinal region) was also dissected and weighed. Finally, gross necropsies were performed to examine for tumor metastases (lungs, liver, lymph nodes).
[0420] Table 4 shows the tumor growth inhibition (TGI%) measured on day 14 of the study in each treatment group. As shown in Table 4, treatment with compound 1 and low-dose ribociclib combination resulted in 63% tumor growth inhibition, while treatment with compound 1 and high-dose ribociclib combination resulted in 72% tumor growth inhibition. Figure 47 shows an analysis of MCF tumor volume over the course of the first 14 days of the study. Figure 48 shows the MCF tumor volume on day 14 of the study. [Table 4]
[0421] On day 16 of the study, mice in experimental groups 3, 4, 5, and 6 received 10 times the amount of ribociclib shown in Table 3. Specifically, mice in experimental groups 2 and 5 received 350 mg / kg of ribociclib, and mice in experimental groups 4 and 6 received 700 mg / kg of ribociclib. On day 17, mice in experimental groups 3, 4, 5, and 6 received the ribociclib doses shown in Table 3. On day 18, the mice's tumors were measured. Table 5 shows the tumor growth inhibition (TGI%) measured on day 18 of the study for each treatment group. As shown in Table 5, treatment with compound 1 and a low dose of ribociclib resulted in 71% tumor growth inhibition, while treatment with compound 1 and a high dose of ribociclib resulted in 79% tumor growth inhibition. Figure 49 shows an analysis of MCF tumor volume over the course of the first 18 days of the study. Figure 50 shows the MCF tumor volume on day 18 of the study. [Table 5]
[0422] The results shown in this embodiment demonstrate that the combination of the MetAP2 inhibitor and CDK4 / 6 inhibitor, more specifically ribociclib, of this disclosure can be used to treat cancer and prevent CDK4 / 6 resistance.
Claims
1. A pharmaceutical composition comprising a MetAP2 inhibitor or a pharma- ceutical acceptable salt thereof for treating breast cancer, said pharmaceutical composition being administered in combination with at least one CDK4 / 6 inhibitor or a pharma- ceutical acceptable salt thereof, said MetAP2 inhibitor being 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof, wherein x is in the range of 1 to about 450, y is in the range of 1 to about 30, and n is in the range of 1 to about 100. The pharmaceutical composition.
2. A pharmaceutical composition comprising a CDK4 / 6 inhibitor or a pharma- ceutical acceptable salt thereof for treating breast cancer, wherein the pharmaceutical composition is administered in combination with at least one MetAP2 inhibitor or a pharma- ceutical acceptable salt thereof; The at least one MetAP2 inhibitor is 【Chemistry 2】 or a pharma- ceutically acceptable salt thereof, wherein x is in the range of 1 to about 450, y is in the range of 1 to about 30, and n is in the range of 1 to about 100. The pharmaceutical composition.
3. 3. The pharmaceutical composition according to claim 1 or 2, wherein the at least one MetAP2 inhibitor, or a pharma- ceutically acceptable salt thereof, and the at least one CDK4 / 6 inhibitor, or a pharma- ceutically acceptable salt thereof, are administered simultaneously or in close temporal proximity.
4. A pharmaceutical composition for treating breast cancer, comprising at least one MetAP2 inhibitor or a pharma- ceutical acceptable salt thereof and at least one CDK4 / 6 inhibitor or a pharma-ceutical acceptable salt thereof, The at least one MetAP2 inhibitor is 【Chemistry 3】 or a pharma- ceutically acceptable salt thereof, wherein x is in the range of 1 to about 450, y is in the range of 1 to about 30, and n is in the range of 1 to about 100.
5. 5. The pharmaceutical composition of any one of claims 1 to 4, wherein the ratio of x to y is in the range of about 30:1 to about 3:
1.
6. 6. The pharmaceutical composition of claim 5, wherein the ratio of x to y is about 11:
1.
7. The CDK4 / 6 inhibitor is selected from the group consisting of palbociclib, abemaciclib, ribociclib, trilaciclib, SHR-6390, FCN-437c, relociclib, milciclib, PF-06873600, XZP-3287, zotilaciclib, BEBT-209, BPI-16350, CS-3002, fadracilib, HS-10342, ON-123300, PF-06842874, TQ-05510, BPI 7. The pharmaceutical composition according to claim 1, wherein the compound is selected from the group consisting of benzodiazepine, benzoyl peroxidase, benzotriazole, benzoyl peroxidase ...
8. The pharmaceutical composition according to any one of claims 1 to 7, wherein the CDK4 / 6 inhibitor is palbociclib or a pharma- ceutically acceptable salt thereof.
9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the CDK4 / 6 inhibitor is abemaciclib or a pharma- ceutically acceptable salt thereof.
10. The pharmaceutical composition according to any one of claims 1 to 9, wherein the CDK4 / 6 inhibitor is ribociclib or a pharma- ceutically acceptable salt thereof.
11. The pharmaceutical composition according to any one of claims 1 to 10, wherein the MetAP2 inhibitor is for administration by subcutaneous injection.
12. The pharmaceutical composition according to any one of claims 1 to 11, wherein the CDK4 / 6 inhibitor is for oral administration.
13. The breast cancer is i) HR+HER2- breast cancer; ii) ER+ breast cancer; iii) HER2-negative breast cancer; iv) Luminal A breast cancer; v) Luminal B breast cancer; vi) triple-negative breast cancer; vii) basal-like breast cancer; or viii) HER2-enriched breast cancer; The pharmaceutical composition according to any one of claims 1 to 12, wherein the pharmaceutical composition is selected from the group consisting of
14. The pharmaceutical composition described in any one of claims 1 to 13, wherein the breast cancer is metastatic breast cancer.
15. The MetAP2 inhibitor, i) Approximately 27 mg / m 2 ; ii) Approximately 36 mg / m 2 ; iii) about 49 mg / m2; or iv) Approximately 65 mg / m 2 ; The pharmaceutical composition according to any one of claims 1 to 14, wherein the pharmaceutical composition is administered in an amount of
